WO2014065434A1 - Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity - Google Patents
Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity Download PDFInfo
- Publication number
- WO2014065434A1 WO2014065434A1 PCT/JP2013/079472 JP2013079472W WO2014065434A1 WO 2014065434 A1 WO2014065434 A1 WO 2014065434A1 JP 2013079472 W JP2013079472 W JP 2013079472W WO 2014065434 A1 WO2014065434 A1 WO 2014065434A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- unsubstituted
- aromatic
- alkyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 *C(OC(c1ccccc1)c1c(cccc2)c2ccc1)=O Chemical compound *C(OC(c1ccccc1)c1c(cccc2)c2ccc1)=O 0.000 description 8
- CDLDJGNSVFBIAG-UHFFFAOYSA-N CC1(C)C(C)(C)OCC1 Chemical compound CC1(C)C(C)(C)OCC1 CDLDJGNSVFBIAG-UHFFFAOYSA-N 0.000 description 1
- ZQBDXEARYNLKKR-GOSISDBHSA-N NC(OCC1)=N[C@@]1(C(F)F)c1cc(NC(c(nc2)ccc2C#N)=O)ccc1F Chemical compound NC(OCC1)=N[C@@]1(C(F)F)c1cc(NC(c(nc2)ccc2C#N)=O)ccc1F ZQBDXEARYNLKKR-GOSISDBHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Definitions
- the present invention relates to a compound which has amyloid ⁇ production inhibitory activity, and is useful as an agent for treating or preventing disease induced by production, secretion and/or deposition of amyloid ⁇ proteins.
- amyloid ⁇ protein the peptide composed of about 40 amino acids residue as is called amyloid ⁇ protein, that accumulates to form insoluble specks (senile specks) outside nerve cells is widely observed. It is concerned that these senile specks kill nerve cells to cause Alzheimer's disease, so the therapeutic agents for Alzheimer's disease, such as decomposition agents of amyloid ⁇ protein and amyloid vaccine, are under investigation.
- Secretase is an enzyme which cleaves a protein called amyloid ⁇ precursor protein (APP) in cell and produces amyloid ⁇ protein.
- the enzyme which controls the production of N terminus of amyloid ⁇ protein is called as ⁇ -secretase (beta-site APP-cleaving enzyme 1, BACE l). It is thought that inhibition of this enzyme leads to reduction of producing amyloid ⁇ protein and that the therapeutic or prophylactic agent for Alzheimer's disease will be created due to the inhibition.
- Patent Documents 1 to 44 and Non-Patent Documents 1 to 3 disclose compounds having a structure similar to those of the compounds of the present invention. Each of these documents discloses each compound is useful as therapeutic agent for Alzheimer's disease, Alzheimer's relating symptoms, or diabetes, but each of substantially disclosed compounds has a structure different from the compounds of the present invention.
- Patent Document 1 WO2007/049532
- Patent Document 2 WO2008/133273
- Patent Document 3 WO2008/133274
- Patent Document 4 WO2009/151098
- Patent Document 5 WO2010/047372
- Patent Document 6 WO2010/113848
- Patent Document 7 WO2011/071057
- Patent Document 8 WO2011/058763
- Patent Document 9 WO2011/070781
- Patent Document 10 WO2011/077726
- Patent Document 11 WO2011/071135
- Patent Document 12 WO2011/071109
- Patent Document 13 WO2012/057247
- Patent Document 14 WO2012/057248
- Patent Document 15 WO2012/147762
- Patent Document 16 WO2012/147763
- Patent Document 17 JP2012/250933A
- Patent Document 18 WO2011/009943
- Patent Document 18 WO2011/020806
- Patent Document 20 WO2011/070029
- Patent Document 21 WO2011/069934
- Patent Document 22 WO2011/138293
- Patent Document 23 WO2007/058583
- Patent Document 24 WO2011/154431
- Patent Document 25 WO2012/110459
- Patent Document 26 WO2012/107371
- Patent Document 27 WO2012/095521
- Patent Document 28 WO2012/006953
- Patent Document 29 WO2011/009898
- Patent Document 31 WO2012/168164
- Patent Document 32 WO2012/168175
- Patent Document 33 WO2013/041499
- Patent Document 34 WO2013/027188
- Patent Document 35 WO2012/095463
- Patent Document 36 WO2012/095469
- Patent Document 37 WO2012/095451
- Patent Document 38 WO2011/057973
- Patent Document 39 WO2011/020806
- Patent Document 40 WO2009/103626
- Patent Document 41 WO2011/154431
- Patent Literature 42 WO2013/083557
- Patent Literature 43 WO2013/110622
- Non-Patent Document 1 Journal of Medicinal Chemistry, 2013, 56(10), pp3980- 3995
- Non-Patent Document 2 Organic & Biomolecular Chemistry 2012, 10, 6758- 6766
- Non-Patent Document 3 Bioorganic & Medicinal Chemistry Letters, 2013,23(14), 4239-4243 -
- the present invention provides compounds which have reducing effects to produce amyloid ⁇ protein, especially BACE l inhibitory activity, and are useful as an agent for treating disease induced by production, secretion and/or deposition of amyloid ⁇ protein.
- the present invention for example, provides the inventions described in the following items.
- X is -C(R3a) (R3b) - ; -C(R3a)(R3b)-C(R3c) (R3d) - or
- L 1 and L 2 are each independently a bond, substituted or unsubstituted alkylene, substituted or unsubstituted alkenylene or substituted or unsubstituted alkynylene, ring A is a substituted or unsubstituted aromatic carbocycle, a substituted or unsubstituted non-aromatic carbocycle, a substituted or unsubstituted aromatic heterocycle or a substituted or unsubstituted non-aromatic heterocycle,
- ring B is a substituted or unsubstituted aromatic carbocycle, a substituted or unsubstituted non-aromatic carbocycle, a substituted or unsubstituted aromatic heterocycle or a substituted or unsubstituted non-aromatic heterocycle,
- R 1 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or unsubstituted cycloalkyl
- R 2a and R 2b are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or
- unsubstituted alkyloxy cyano or substituted or unsubstituted cycloalkyl, preferably hydrogen, halogen, substituted or unsubstituted alkyl, or substituted or
- R 3a , R b , R 3c and R 3d are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, cyano or substituted or unsubstituted cycloalkyl, preferably hydrogen, halogen, or substituted or
- R 2a and R 3a attached to adjacent carbon atoms, together with the carbon atoms to which they are attached, may form
- R 3a and R 3b together with the carbon atom to which they are attached may form
- R 1 and R 2a together with the carbon atoms to which they are attached may form [Chemical Formula 4] and when R 1 and R 2a together with the carbon atoms to which they are attached form the above (vii), then R 3a and R 3b together with the carbon atom to which they are attached may form
- R 5 is halogen or substituted or unsubstituted alkyl
- R 6 is substituted or unsubstituted alkyl
- R 7 is halogen or substituted or unsubstituted alkyl
- R 8a and R 8b are each independently hydrogen or substituted or unsubstituted alkyl, n is an integer of 0 to 2,
- n 1 or 2 ,
- p is an integer of 0 to 2
- q is an integer of 1 or 2
- L l and L 2 are each independently a bond, substituted or unsubstituted alkylene, substituted or unsubstituted alkenylene or substituted or unsubstituted alkynylene, ring A is a substituted or unsubstituted aromatic carbocycle, a substituted or unsubstituted non-aromatic carbocycle, a substituted or unsubstituted aromatic heterocycle or a substituted or unsubstituted non-aromatic heterocycle,
- ring B is a substituted or unsubstituted aromatic carbocycle, a substituted or unsubstituted non-aromatic carbocycle, a substituted or unsubstituted aromatic heterocycle or a substituted or unsubstituted non-aromatic heterocycle
- R 1 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or unsubstituted cycloalkyl
- R 2a , R2t>
- R3c an( j R3d are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, cyano or substituted or unsubstituted cycloalkyl
- R 2a and R 3a attached to adjacent carbon atoms, together with the carbon atoms to which they are attached, may form
- R 5 is halogen or substituted or unsubstituted alkyl, n is an integer of 0 to 2, m is an integer of 1 or 2,
- X is -C(R 3 a)(R3b) - ; -C(R3f (R 3b ) C(R 3c )(R 3d )- or
- L 1 and L 2 are each independently a bond, substituted or unsubstituted alkylene, substituted or unsubstituted alkenylene or substituted or unsubstituted alkynylene, ring A is a substituted or unsubstituted aromatic carbocycle, a substituted or unsubstituted non-aromatic carbocycle, a substituted or unsubstituted aromatic heterocycle or a substituted or unsubstituted non-aromatic heterocycle,
- ring B is a substituted or unsubstituted aromatic carbocycle, a substituted or unsubstituted non-aromatic carbocycle, a substituted or unsubstituted aromatic heterocycle or a substituted or unsubstituted non-aromatic heterocycle,
- R 1 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or unsubstituted cycloalkyl
- R 2a and R 2 are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or
- R3a ) R3b ; R3c an( j R3d are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, cyano or substituted or unsubstituted cycloalkyl,
- R 2a and R 3a attached to adjacent carbon atoms, together with the carbon atoms to which they are attached, may form
- R3a and R 3b together with the carbon atom to which they are attached may form [Chemical Formula 12] wherein R 5 is halogen or substituted or uhsubstituted alkyl,
- R 6 is substituted or unsubstituted alkyl
- R 8a and R 8b are each independently hydrogen or substituted or unsubstituted alkyl, n is an integer of 0 to 2, and
- n 1 or 2
- a compound wherein X is -C(R 3a )(R 3b )-, R 1 is substituted or unsubstituted alkyl, and R 2a and R 3a attached to adjacent carbon atoms, together with the carbon atoms to which they are attached, may form the above group (iv), and
- R 1 is haloalkyl
- at least one of R 2a , R 2b , R 3a , R 3b , R 3c and R 3d is halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, cyano or substituted or unsubstituted cycloalkyl, preferably at least one of R 2a , R 2b , R 3a , R 3b , R 3c and R 3d is halogen or substituted or unsubstituted alkyl, or a pharmaceutically acceptable salt thereof.
- R B 1 is halogen or cyano
- R B2 is substituted or unsubstituted alkyl, halogen, hydroxy, substituted or unsubstituted amino or substituted or unsubstituted cycloalkyl,
- R B3 is halogen
- R B4 is substituted or unsubstituted alkyl, or substituted or unsubstituted alkyloxy, and
- R BS is hydrogen or substituted or unsubstituted amino
- R B4 is substituted or unsubstituted alkyloxy
- R B6 is halogen or cyano
- R B7 is hydrogen, substituted or unsubstituted alkyl, halogen, hydroxy, substituted or unsubstituted amino or substituted or unsubstituted cycloalkyl
- R B4 is substituted or unsubstituted alkyl or substituted or unsubstituted alkyloxy
- R B5 is hydrogen or substituted or unsubstituted amino
- R B8 and R B9 are each independently hydrogen or substituted or unsubstituted alkyl, or a pharmaceutically acceptable salt thereof.
- R B6 is halogen or cyano
- R B7 is alkyl, haloalkyl, halogen, hydroxy, amino or cycloalkyl,
- R B4 is alkyl, haloalkyl, alkyloxy, or haloalkyloxy, and
- R B5 is hydrogen or amino
- R 4 is hydrogen or halogen
- a pharmaceutical composition comprising the compound according to any one of items (l), (l- l) to (1-6) and (2) to (18), a pharmaceutically acceptable salt thereof.
- a pharmaceutical composition having BACE 1 inhibitory activity comprising the compound according to any one of items (l), (l- l) to (1-6) and (2) to (18), or a pharmaceutically acceptable salt thereof.
- a method for inhibiting BACE 1 activity comprisin administering the compound according to any one of items (l), (l" l) to (1-6) and (2) to (18), or a pharmaceutically acceptable salt thereof.
- a method for treating or preventing diseases induced by production, secretion or deposition of amyloid ⁇ proteins comprising administering the compound according to any one of items (l), (l- l) to (1'6) and (2) to (18) or a pharmaceutically acceptable salt thereof.
- a method for treating or preventing dementia of the Alzheimer's type comprising administering the compound according to any one of items ( ⁇ ), (l" l) to (l- 6) and (2) to (18), or a pharmaceutically acceptable salt thereof.
- a pharmaceutical composition according to item (19) or (20) for treating or preventing dementia of the Alzheimer's type is provided.
- the compound of the present invention has BACE 1 inhibitory activity and is useful as an agent for treating or preventing disease induced by production, secretion or deposition of amyloid ⁇ proteins such as dementia of the Alzheimer's type.
- halogen includes fluorine, chlorine, bromine, and iodine. Fluorine and chlorine are preferable.
- alkyl includes linear or branched alkyl of a carbon number of 1 to 15, for example, a carbon number of 1 to 10, for example, a carbon number of 1 to 6, and for example, a carbon number of 1 to 4.
- Examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, isohexyl, n-heptyl, isoheptyl, n-octyl, isopctyl, n-nonyl and n-decyl.
- Examples are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec- butyl, tert'butyl and n-pentyl.
- alkyl is methyl, ethyl, n-propyl, isopropyl or tert-butyl.
- alkenyl includes linear or branched alkenyl of a carbon number or 2 to 15, for example, a carbon number of 2 to 10, for example, a carbon number of 2 to 6, and for example, a carbon number of 2 to 4, having one or more double bonds at any available positions.
- Examples include vinyl, allyl, propenyl, isopropenyl, butenyl, isobutenyl, prenyl, butadienyl, pentenyl, isopentenyl, pentadienyl, hexenyl, isohexenyl, hexadienyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, tridecenyl, tetradecenyl and pentadecenyl.
- Examples are vinyl, allyl, propenyl, isopropenyl and butenyl.
- alkynyl includes a linear or branched alkynyl of a carbon number of 2 to 15, for example, a carbon number of 2 to 10, for example, a carbon number of 2 to 8, for example, a carbon number of 2 to 6, and for example, a carbon number of 2 to 4 having one or more triple bonds at optionally positions.
- Specific examples are ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl and decynyl. These may have further a double bond at any available position.
- Examples are ethynyl, propynyl, butynyl and pentynyl.
- alkylene include a linear or branched divalent carbon chain of a carbon number of 1 to 15, for example, a carbon number of 1 to 10, for example, a carbon number of 1 to 6, and for example a carbon number of 1 to 4. Examples are methylene, dimethylene, trimethylene, tetramethylene, pentamethylene and hexamethylene.
- Alkylene portion in “alkylenedioxy” is the same as the above “alkylene”.
- Examples are methylenedioxy and dimethylenedioxy.
- alkenylene includes. a linear or branched divalent carbon chain of a carbon number of 2 to 15, for example, a carbon number of 2 to 10, for example, a carbon number of 2 to 6, and for example, a carbon number of 2 to 4, having one or more double bonds at any available position.
- Examples are vinylene, propenylene, butenylene, butadienylene, methylpropenylene, pentenylene and hexenylene.
- alkynylene includes a linear or branched divalent carbon chain of a carbon number of 2 to 15, for example, a carbon number of 2 to 10, for example, a carbon number of 2 to 6, and for example, a carbon number of 2 to 4, having one or more triple bonds at any available position. These may have further a double bond at any available position. Examples are ethynylene, propynylene, butynylene, pentynylene and hexynylene.
- aromatic carbocyclyl includes an aromatic hydrocarbon group which is monocyclic or which consists of two or more rings. Examples are an aromatic hydrocarbon group of a carbon number of 6 to 14, and specific examples are phenyl, naphthyl, anthryl and phenanthryl.
- aromatic carbocyclyl is phenyl
- non-aromatic carbocyclyl includes saturated carbocyclyl or unsaturated non-aromatic carbocyclyl which is monocyclic or which consists of two or more rings.
- a "non-aromatic carbocyclyl" of two or more rings includes a fused cyclic group wherein a non-aromatic monocyclic carbocycle or a non-aromatic carbocycle of two or more rings is fused with a ring of the above "aromatic
- non-aromatic carbocyclyl also includes a cyclic group having a bridge or a cyclic group to form a spiro ring as follows ⁇
- non-aromatic monocyclic carbocyclyl includes a group having 3 to
- 16 carbon atoms for example, 3 to 12 carbon atoms, and for example, 4 to 8 carbon atoms.
- Examples are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclohexadienyl.
- non-aromatic carbocyclyl consisting of two or more rings includes a group having 6 to 14 carbon atoms, and examples are indanyl, indenyl, acenaphthyl, tetrahydronaphthyl and fluorenyl.
- cycloalkyl includes a carbocyclic group of a carbon number of 3 to 10, for example, a carbon number of 3 to 8, and for example, a carbon number 4 to 8. Examples are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl and cyclodecyl.
- cycloalkane includes a carbocycle of a carbon number of 3 to 10, for example, a carbon number of 3 to 8, and for example, a carbon number 4 to 8. Examples are cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane and cyclodecane.
- Cycloalkyl portion in “cycloalkylalkyl” and “cycloalkylamino” are the same as the above “cycloalkane”. , .
- aromatic heterocyclyl includes an aromatic group which is monocyclic, or which consists of two or more rings, containing one or more of heteroatoms selected independently from oxygen, sulfur and nitrogen atoms.
- aromatic heterocyclyl of two or more rings includes a fused cyclic group wherein aromatic monocyclic heterocyclyl or non-aromatic heterocyclyl consisting of two or more rings is fused with a ring of the above "aromatic carbocyclyl".
- aromatic monocyclic heterocyclyl includes a 5- to 8-membered group, and for example, 5- to 6- membered group.
- Examples are pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazolyl, triazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, oxazolyl, oxadiazolyl, isothiazolyl, thiazolyl and thiadiazolyl.
- aromatic bicyclic heterocyclyl includes a 9- to 10-membered group, and examples are indolinyl, isoindolinyl, iridazolinyl, indolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl, quinoxalinyl, purinyl, pteridinyl, benzimidazolyl, benzisoxazolyl, benzoxazolyl, benzoxadiazolyl, benzisothiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, imidazopyridyl, triazolopyridyl, imidazothiazolyl, pyrazinopyridazinyl, oxazolopyridyl and thiazo
- non-aromatic heterocyclyl includes a non-aromatic group which is monocyclic, or which consists of two or more rings, containing one or more of heteroatoms selected independently from oxygen, sulfur and nitrogen atoms.
- a “non-aromatic heterocyclyl” of two or more rings includes a fused cyclic group wherein a non-aromatic monocyclic heterocyclyl or a non-aromatic heterocyclyl of two or more rings is fused with a ring of the above "aromatic carbocyclyl", “non- aromatic carbocyclyl” and/or "aromatic heterocyclyl”.
- non-aromatic heterocyclyl also includes a cyclic group having a bridge or a cyclic group to form a spiro ring as follows:
- a non-aromatic monocyclic heterocyclyl includes a 3- to 8- membered ring, and for example, 4", 5- or 6-membered ring.
- Examples are dioxanyl, thiiranyl, oxiranyl, oxetanyl, oxathiolanyl, azetidinyl, thianyl, thiazolidinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, dihydropyridyl, tetrahydropyridyl, tetrahydrofuryl, tetrahydropyranyl,
- hexahydropyrimidinyl dioxolanyl, dioxazinyl, aziridinyl, dioxolinyl, oxepanyl, thiolanyl, thiinyl and thiazinyl.
- Examples of a non-aromatic heterocyclyl of two or more rings includes a 9 to
- hydroxyalkyl includes a group wherein one or more hydrogen atoms attached to one or more carbon atoms of the above “alkyl” are replaced with one or more hydroxy groups. Examples are hydroxymethyl, 1-hydroxyethyl, 2- hydroxyethyl, 1-hydroxypropyl, 2-hydroxypropyl and 1,2-dihydroxyethyl.
- hydroxyalkyl is hydroxymethyl
- alkyloxy includes a group wherein an oxygen atom is substituted with the above “alkyl”. Examples are methyloxy, ethyloxy, n-propyloxy, isopropyloxy, n-butyloxy, tert-butyloxy, isobutyloxy, sec-butyloxy, pentyloxy, isopentyloxy and hexyloxy.
- alkyloxy is methyloxy, ethyloxy, n-propyloxy, isopropyloxy or tert-butyloxy.
- alkenyloxy includes a group wherein an oxygen atom is substituted with the above “alkenyl”. Examples are vinyloxy, allyloxy, 1- propenyloxy, 2-butenyloxy, 2-pentenyloxy, 2-hexenyloxy, 2-heptenyloxy and 2" octenyloxy.
- alkynyloxy includes a group wherein an oxygen atom is substituted with the above “alkynyl”. Examples are ethynyloxy, 1-propynyloxy, 2- propynyloxy, 2-butynyloxy, 2-pentynyloxy, 2-hexynyloxy, 2-heptynyloxy and 2- octynyloxy.
- haloalkyl includes a group wherein one or more hydrogen atoms attached to one or more carbon atoms of the above “alkyl” are replaced with one or more above "halogen".
- Examples are monofluoromethyl, monofluoroethyl, monofluoropropyl, difluoromethyl, 2,2,3,3,3-pentaflUoropropyl, monochloromethyl, trifluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl, 2,2- difluoroethyl, 1, 1-difluoroethyl, 2,2,2-trifluoroethyl, i,2"dibromoethyl, and 1, 1, 1" trifluoropropan-2-yl.
- Examples are monofluoromethyl, difluoromethyl,
- trifluoromethyl and 2,2-difluoroethyl examples are monofluoromethyl and difluoromethyl.
- haloalkenyl includes a group wherein one or more hydrogen atoms attached to one or more carbon atoms of the above “alkenyl” are replaced with one or more above "halogen". Examples are monofluorovinyl, monofluoroallyl, monofluoropropenyl, difluorovinyl, difluoroallyl and difluoropropenyl.
- haloalkynyl includes a group wherein one or more hydrogen atoms attached to one or more carbon atoms of the above "alkynyl” are replaced with one or more above "halogen”. Examples are fluoroethynyl, monofluoropropynyl, difluoropropynyl, monofluorobutynyl, chloroethynyl, monochloropropynyl,
- haloalkyloxy includes a group wherein an oxygen atom is substituted with the above “haloalkyl”. Examples are monofluoromethyloxy, monofluoroethyloxy, difluoromethyloxy, 1, l-difluoroethyloxy, 2,2-difluoroethyloxy, trifluoromethyloxy, trichloromethyloxy, 2,2,2-trifluoroethyloxy and trichloroethyloxy.
- haloalkyloxy is difluoromethyloxy, 2, 2,2- difluoroethyloxy, trifluoromethyloxy, 2,2,2-trifluoroethyloxy, or trichloromethyloxy.
- cyanoalkyloxy includes a group wherein the above “alkyloxy” is substituted with a cyano group. Examples are cyanomethyloxy and
- alkyloxyalkyl includes a group wherein the above “alkyl” is substituted with the above “alkyloxy”. Examples are methoxymethyl, methoxyethyl and ethoxymethyl.
- alkyloxyalkyloxy includes a group wherein the above “alkyloxy” is substituted with the above “alkyloxy”. Examples are methyloxynlethyloxy, methyloxyethyloxy, ethyloxymethyloxy and ethyloxyethyloxy.
- alkylcarbortyl includes a group wherein a carbonyl group is substituted with the above “alkyl”. Examples are methylcarbonyl, ethylcarbonyl, n- propylcarbonyl, isopropylcarbonyl, tert-butylcarbonyl, isobutylcarbonyl, sec- butylcarbonyl, pentylcarbonyl, isopentylcarbonyl and hexylcarbonyl. Examples are methylcarbonyl, ethylcarbonyl and n-propylcarbonyl.
- alkenylcarbonyl includes a group wherein a carbonyl group is substituted with the above “alkenyl”. Examples are ethylenylcarbonyl,
- alkynylcarbonyl includes a group wherein a carbonyl group is substituted with the above “alkynyl”. Examples are ethynylcarbonyl,
- monoalkylamino includes a group wherein a hydrogen atom attached to a nitrogen atom of an amino group is replaced with the above “alkyl”. Examples are methylamino, ethylamino and isopropylamino.
- “monoalkylamino,” is methylamino or ethylamino.
- dialkylamino includes a group wherein two hydrogen atoms attached to a nitrogen atom of an amino group are replaced with two above “alkyl”. These two alkyl groups may be the same or different. Examples are dimethylamino, diethylamino, ⁇ , ⁇ -diisopropylamino, N-methyl-N-ethylamino and N-isopropyl-N- ethylamino.
- dialkylamino is dimethylamino or diethylamino.
- alkylsulfonyl includes a group wherein a sulfonyl group is substituted with the above “alkyl”. Examples are methylsulfonyl, ethylsulfonyl, propylsuifonyl, isopropylsulfonyl, tert-butylsulfonyl, isobutylsulfonyl and sec- butylsulfonyl.
- alkylsulfonyl is methylsulfonyl or ethylsulfonyl.
- alkenylsulfonyl includes a group wherein a sulfonyl group is substituted with the above “alkenyl”. Examples are ethylenylsulfonyl,
- alkynylsulfonyl includes a group wherein a sulfonyl group is substituted with the above “alkynyl”. Examples are ethynylsulfonyl,
- monoalkylcarbonylamino includes a group wherein a hydrogen atom attached to a nitrogen atom of an amino group is replaced with the above “alkylcarbonyl”. Examples are methylcarbonylamino, ethylcarbonylamino, propylcarbonylamino, isopropylcarbonylamino, tert-butylcarbonylamino, isobutylcarbonylamino and sec-butylcarbonylamino.
- "monoalkylcarbonylamino” is methylcarbonylamino or ethylcarbonylamino.
- dialkylcarbonylamino includes a group wherein two hydrogen atoms attached to a nitrogen atom of an amino group are replaced with two above “alkylcarbonyl". These two alkylcarbonyl groups may be the same or different. Examples are dimethylcarbonylamino, diethylcarbonylamino and N,N- diisopropylcarbonylamino. In one embodiment, “dialkylcarbonylamino” is dimethylcarbonylamino or diethylcarbonylamino.
- monoalkylsulfonylamino includes a group wherein a hydrogen atom attached to a nitrogen atom of an amino group is replaced with the above “alkylsulfonyl”: Examples are methylsulfonylamino, ethylsulfonylamino, propylsulfonylamino, isopropylsulfonylamino, tert-butylsulfonylamino,
- monoalkylsulfonylamino is methylsulfonylamino or ethylsulfonylamino.
- dialkylsulfonylamino includes a group wherein two hydrogen atoms attached to a nitrogen atom of art amino group are replaced with two above “alkylsulfonyl". These two alkylsulfonyl groups may be the same or different. Examples are dimethylsulfonylamino, diethylsulfonylamino and N,N- diisopropylsulfonylamino. In one embodiment, "dialkylsulfonylamino" is
- alkylimino includes a group wherein a hydrogen atom attached to a nitrogen atom of an imino group is replaced with the above “alkyl”. Examples are methylimino, ethylimino, n-propylimino and isopropylimino.
- alkenylimino includes a group wherein a hydrogen atom attached to a nitrogen atom of an imino group is replaced with the above “alkenyl”. Examples are ethylenylimino and propenylimino.
- alky nylimino includes a group wherein a hydrogen atom attached to a nitrogen atom of an imino group is replaced with the above “alkynyl”.
- Examples are ethynylimino and propynylimino.
- alkylcarbonylimino includes a group wherein a hydrogen atom attached to a nitrogen atom of an imino group is replaced with the above
- alkylcarbonyl examples are methylcarbonylimino, ethylcarbonylimino, n- propylcarbonylimino and isopropylcarbonylimino.
- alkenylcarbonylimino includes a group wherein a hydrogen atom attached to a nitrogen atom of an imino group is replaced with the above “alkenylcarbonyl”. Examples are ethylenylcarbonylimino and
- alkynylcarbonylimino includes a group wherein a hydrogen atom attached to a nitrogen atom of an imino group is replaced with the above “alkynylcarbonyl”. Examples are ethynylcarbonylimino and propynylcarbonylimino.
- alkyloxyimino includes a group wherein a hydrogen atom attached to a nitrogen atom of an imino group is replaced with the above “alkyloxy”. Examples are methyloxyimino, ethyloxyimino, n-propyloxyimino and
- alkenyloxyimino includes a group wherein a hydrogen atom attached to a nitrogen atom of an imino group is replaced with the above
- alkenyloxy examples are ethylenyloxyimino and propenyloxyimino.
- alkynyloxyimino includes a group wherein a hydrogen atom attached to a nitrogen atom of an imino group is replaced with the above
- alkynyloxy examples are ethynyloxyimino and propynyloxyimino.
- alkylcarbonyloxy includes a group wherein an oxygen atom is substituted with the above “alkylcarbonyl”. Examples are methylcarbonyloxy, ethylcarbonyloxy, propylcarbonyloxy, isopropylcarbonyloxy, tert-butylcarbonyloxy, isobutylcarbonyloxy and sec-butylcarbonyloxy. In one embodiment,
- alkylcarbonyloxy is methylcarbonyloxy or ethylcarbonyloxy.
- alkenylcarbonyloxy includes a group wherein an oxygen atom is substituted with the above “alkenylcarbonyl”. Examples are
- alkynylcarbonyloxy includes a group wherein an oxygen atom is substituted with the above “alkynylcarbonyl”. Examples are ethynylcarbonyloxy . and propynylcarbonyloxy.
- alkyloxycarbonyl includes a group wherein a carbonyl group is substituted with the above “alkyloxy”. Examples are methyloxycarbonyl,
- alkyloxycarbonyl is methyloxycarbonyl, ethyloxycarbonyl or propyloxycarbonyl.
- alkenyloxycarbonyl includes a group wherein a carbonyl group is substituted with the above “alkenyloxy”. Examples are ethylenyloxycarbonyl, propenyloxycarbonyl and butenyloxycarbonyl.
- alkynyloxycarbonyl includes a group wherein a carbonyl group is substituted with the above “alkynyloxy”. Examples are ethynyloxycarbonyl, propynyloxycarbonyl and butynyloxyarbonyl.
- alkylsulfanyl includes a group wherein a hydrogen atom attached to a sulfur atom of a sulfanyl group is replaced with the above “alkyl”.
- Examples are methylsulfanyl, ethylsulfanyl, n-propylsulfanyl, isopropylsulfanyl, tert'butylsulfanyl and isobutylsulfanyl.
- cyanoalkylsulfanyl includes a group wherein the above
- alkylsulfanyl is substituted with a cyano group. Examples are
- alkenylsulfanyl includes a group wherein a.hydrogen atom attached to a sulfur atom of a sulfanyl group is replaced with the above “alkenyl”.
- Examples are ethylenylsulfanyl, propenylsulfanyl and butenylsulfanyl.
- alkynylsulfanyl includes a group wherein a hydrogen atom attached to a sulfur atom of a sulfanyl group is replaced with the above “alkynyl”. Examples are ethynylsulfanyl, propynylsulfanyl and butynylsulfanyl.
- alkylsulfinyl includes a group wherein a sulfinyl group is substituted with the above “alkyl”. Examples are methylsulfinyl, ethylsulfinyl, n- propylsulfinyl and isopropylsulfinyl.
- alkenylsulfinyl includes a group wherein a sulfinyl group is substituted with the above “alkenyl”. Examples are ethylenylsulfinyl,
- alkynylsulfinyl includes a group wherein a sulfinyl group is substituted with the above “alkynyl”. Examples are ethynylsulfinyl,
- monoalkylcarbamoyl includes a group wherein a hydrogen atom attached to a nitrogen atom of a carbamoyl group is replaced with the above “alkyl”. Examples are methylcarbamoyl, ethylcarbamoyl, n-propylcarbamoyl and isopropylcarbamoyl.
- dialkylcarbamoyl includes a group wherein two hydrogen atom attached to a nitrogen atom of a carbamoyl group are replaced with two above “alkyl”. These two alkyl groups may be the same or different. Examples are
- monoalkylsulfamoyl includes a group wherein a hydrogen atom attached to a nitrogen atom of a sulfamoyl group is replaced with the above “alkyl”. Examples are methylsulfamoyl, ethylsulfamoyl, n-propylsulfamoyl and isopropylsulfamoyl.
- dialkylsulfamoyl includes a group wherein two hydrogen atoms attached to a nitrogen atom of a sulfamoyl group are replaced with two above “alkyl”. These two alkyl groups may be the same or different. Examples are dimethylsulfamoyl, diethylsulfamoyl and N-methyl-N-ethylsulfamoyl.
- trialkylsilyl includes a group wherein a silicon atom is substituted with three above “alkyl”. These three alkyl groups may be the same or different. Examples are trimethylsilyl, triethylsilyl and tert-butyldimethylsilyl.
- alkylidene includes a divalent group derived from alkane by removing two hydrogen atoms from the same carbon atom. Examples are methylidene, ethylidene, propylidene, isopropylidene, butylidene, pentylidene and hexylidene.
- alkenyl portion of "alkenylcarbonylamino", “alkyloxyalkenyloxy”, “alkenylsulfanyl” and “alkenylamino” means the above “alkenyl”.
- alkynyl portion of "alkynylcarbonylamino", “alkyloxyalkynyloxy”, “alkynylsulfanyl” and “alkynylamino” means the above “alkynyl”.
- alkyloxyalkenyloxy "alkyloxyalkynyloxy", “alkylcarbonyl", "monoalkylcarbamoyl", “dialkylcarbamoyl", "hydroxyalkylcarbamoyl", “alkyloxyamino”, "alkylsulfanyl”, “monoalkylsulfonylamino", “dialkylsulfonylamino” "alkylsulfonylalkylamino", “alkylsulfonylimino", "alkylsulfinylamino", “alkylsulfinylalkylamino",
- alkylsulfinylimino "monoalkylsulfamoyl", dialkylsulfamoyl", "aromatic carbocyclylalkyl", “non-aromatic carbocyclylalkyl", “aromatic heterocyclylalkyl” and “non-aromatic heterocyclylalkyl", "aromatic carbocyclylalkyloxy", “non-aromatic carbocyclylalkyloxy", “aromatic heterocyclylalkyloxy" and "non-aromatic
- heterocyclylalkyloxy "aromatic carbocyclylalkyloxycarbonyl", “non-aromatic carbocyclylalkyloxycarbonyl", “aromatic heterocyclylalkyloxycarbonyl” and “non- aromatic heterocyclylalkyloxycarbonyl", "aromatic carbocyclylalkyloxyalkyl", “non- aromatic carbocyclylalkyloxyalkyl”, “aromatic heterocyclylalkyloxyalkyloxyalkyl” and “non- aromatic heterocyclylalkyloxyalkyl", and "aromatic carbocyclylalkylamino", “non- aromatic carbocyclylalkylamino", “aromatic heterocyclylalkylamino” and “non- aromatic heterocyclylalkylamino", "aromatic carbocyclylalkylcarbamoyl", “non- aromatic carbocyclylalkylcarbamoyl", "
- aromatic carbocyclylalkyl includes alkyl substituted with one or more above “aromatic carbocyclyl”. Examples are benzyl, phenethyl,
- aromatic carbocyclylalkyl is benzyl, phenethyl or benzhydryl.
- non-aromatic carbocyclylalkyl includes alkyl substituted with one or more above “non-aromatic carbocyclyl". Also, “non-aromatic carbocyclylalkyl' includes a “non-aromatic carbocyclyl alkyl” wherein the alkyl portion thereof is substituted with one or more above “aromatic carbocyclyl”. Examples are
- aromatic heterocyclyl alkyl includes alkyl substituted with one or more above “aromatic heterocyclyl”. Also, “aromatic heterocyclyl alkyl” includes “aromatic heterocyclyl alkyl” wherein the alkyl portion thereof is
- aromatic carbocyclyl substituted with one or more above "aromatic carbocyclyl", and/or "non-aromatic carbocyclyl".
- aromatic carbocyclyl examples are pyridylmethyl, furanylmethyl, imidazolylmethyl, indolylmethyl, benzothiophenylmethyl, oxazolylmethyl, isoxazolylmethyl, thiazolylmethyl, isothiazolylmethyl, pyrazolylmethyl, isopyrazolylmethyl, pyrrolidinylmethyl, benzoxazolylmethyl and groups of the formula of
- non-aromatic heterocyclyl alkyl includes alkyl substituted with one or more above “non-aromatic heterocyclyl”. Also, “non-aromatic heterocyclyl alkyl” includes a “non-aromatic heterocyclylalkyl” wherein the alkyl portion thereof is substituted with one or more above “aromatic carbocyclyl", “non- aromatic carbocyclyl” and/or “aromatic heterocyclyl”. Examples are
- aromatic carbocyclylalkyloxy includes alkyloxy substituted with one or more above “aromatic carbocyclyl”. Examples are benzyloxy, phenethyloxy, phenylpropyloxy, benzhydryloxy, trityloxy, naphthylmethyloxy and a group of the formula of
- non-aromatic carbocyclylalkyloxy includes alkyloxy substituted with one or more above “non-aromatic carbocyclyl”. Also, “non-aromatic carbocyclylalkyloxy” includes a “non-aromatic carbocyclylalkyloxy” wherein the alkyl portion thereof is substituted with one or more above “aromatic carbocyclyl”.
- Examples are cyclopropylmethyloxy, cyclobutylmethyloxy, cyclopentylmethyloxy, cyclohexylmethyloxy and a group of the formula of
- aromatic heterocyclyl alkyloxy includes alkyloxy substituted with one or more above “aromatic heterocyclyl”. Also, “aromatic
- heterocyclylalkyloxy includes "aromatic heterocyclylalkyloxy” wherein the alkyl portion thereof is substituted with one or more above “aromatic carbocyclyl", and/or "non-aromatic carbocyclyl". Examples are pyridylmethyloxy, furanylmethyloxy, imidazolylmethyloxy, indolylmethyloxy, benzothiophenylmethyloxy,
- non-aromatic heterocyclylalkyloxy includes alkyloxy
- non- aromatic heterocyclylalkyloxy includes a “non-aromatic heterocyclylalkyloxy” whertein the alkyl portion thereof is substituted with one or more above "aromatic carbocyclyl", “non-aromatic carbocyclyl” and/or "aromatic heterocyclyl".
- Examples are tetrahydropyranylmethyloxy, morpholinylmethyloxy, morpholinylethyloxy, piperidinylmethyloxy, piperazinylmethyloxy and groups of the formula of
- aromatic carbocyclyl alkyloxycarbonyl includes
- alkyloxycarbonyl substituted with one or more above "aromatic carbocyclyl”.
- Examples are benzyloxycarbonyl, phenethyloxycarbonyl, phenylpropyloxycarbonyl, benzhydryloxycarbonyl, trityloxycarbonyl, naphthylmethyloxycarbonyl and a group of the formula of
- non-aromatic carbocyclylalkyloxycarbonyl includes alkyloxycarbonyl substituted with one or more above “non-aromatic carbocyclyl”
- non-aromatic carbocyclylalkyloxycarbonyl includes “non-aromatic carbocyclylalkyloxycarbonyl” wherein the alkyl portion thereof is substituted wi one or more above “aromatic carbocyclyl”. Examples are
- aromatic heterocyclyl alkyloxycarbonyl includes
- aromatic heterocyclyl alkyloxycarbonyl includes “aromatic heterocyclyl
- alkyloxycarbonyl wherein the alkyl portion thereof is substituted with one or more above “aromatic carbocyclyl", and/or "non-aromatic carbocyclyl".
- aromatic carbocyclyl and/or "non-aromatic carbocyclyl”. Examples are pyridylmethyloxycarbonyl, furanylmethyloxycarbonyl, imidazolylmethyloxycarbonyl, indolylmethyloxycarbonyl, benzothiophenylmethyloxycarbonyl,
- non-aromatic heterocyclyl alkyloxycarbonyl includes
- non-aromatic heterocyclyl alkyloxycarbonyl substituted with one or more above “non-aromatic heterocyclyl.
- non-aromatic heterocyclyl alkyloxycarbonyl includes “non-aromatic
- heterocyclyl alkyloxycarbonyl wherein the alkyl portion thereof is substituted with one or more above “aromatic carbocyclyl", “non-aromatic carbocyclyl” and/or
- aromatic heterocyclyl examples are tetrahydropyranylmethyloxycarbonyl, morpholinylmethyloxycarbonyl, morpholinylethyloxycarbonyl, piperidinylmethyloxycarbonyl, piperazinylmethyloxycarbonyl and groups of the formula of
- aromatic carbocyclylalkyloxyalkyl includes alkyloxyalkyl substituted with one or more above “aromatic carbocyclyl”. Examples are benzyloxymethyl, phenethyloxymethyl, phenylpropyloxymethyl,
- non-aromatic carbocyclylalkyloxyalkyl includes alkyloxyalkyl substituted with one or more above “non-aromatic carbocyclyl”. Also, “non-aromatic carbocyclylalkyloxyalkyl” includes a “non-aromatic carbocyclylalkyloxyalkyl” wherein the alkyl portion attached to a non-aromatic carbocyclyl is substituted with one or more above "aromatic carbocyclyl”. Examples are
- aromatic heterocyclylalkyloxyalkyl includes alkyloxyalkyl substituted with one , or more above “aromatic heterocyclyl”. Also, “aromatic heterocyclylalkyloxyalkyl” includes “aromatic heterocyclylalkyloxyalkyl” wherein the alkyl portion attached to aromatic heterocyclyl is substituted with one or more above “aromatic carbocyclyl” and/or “non-aromatic carbocyclyl”. Examples are
- non-aromatic heterocyclylalkyloxyalkyl includes alkyloxyalkyl substituted with one or more above “non-aromatic heterocyclyl”. Also, “non- aromatic heterocyclylalkyloxyalkyl” includes “non-aromatic
- heterocyclylalkyloxyalkyl wherein the alkyl portion attached to non-aromatic heterocyclyl is substituted with one or more above "aromatic carbocyclyl", “non- aromatic carbocyclyl” and/or "aromatic heterocyclyl”. Examples are:
- aromatic carbocyclylalkylamino includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of an amino group is replaced with the above “aromatic carbocyclylalkyl”. Examples are benzylamino,
- non-aromatic carbocyclylalkylamino includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of an amino group is replaced with the above “non-aromatic carbocyclylalkyl”. Examples are
- aromatic heterocyclylalkylamino includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of an amino group is replaced with the above “aromatic heterocyclylalkyl”. Examples are pyridylmethylamino, furanylmethylamino, imidazolylmethylamino, indolylmethylamino,
- non-aromatic heterocyclylalkylamino includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of an amino group is replaced with the above “non-aromatic heterocyclyl alkyl”. Examples are
- aromatic carbocyclylalkylcarbamoyl includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of a carbamoyl group is replaced with the above “aromatic carbocyclylalkyl”.
- Examples are benzylcarbamoyl, phenethylcarbamoyl, phenylpropylcarbamoyl, benzhydrylcarbamoyl, tritylcarbamoyl, naphthylmethylcarbamoyl and dibenzylcarbamoyl.
- non-aromatic carbocyclylalkylcarbamoyl includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of a carbamoyl group is replaced with the above “non-aromatic carbocyclylalkyl”. Examples are cyclop ropylmethylcarbamoyl, cyclobutylmethylcarbamoyl,
- aromatic heterocyclylalkylcarbamoyl includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of a carbamoyl group is replaced with the above “aromatic heterocyclylalkyl”. Examples are
- oxazolylmethylcarbamoyl isoxazolylmethylcarbamoyl, thiazolylmethylcarbamoyl, isothiazolylmethylcarbamoyl, pyrazolylmethylcarbamoyl,
- non-aromatic heterocyclylalkylcarbamoyl includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of a carbamoyl group is replaced with the above “non-aromatic heterocyclyl alkyl”. Examples are tetrahydropyranylmethylcarbamoyl, morpholinylethylcarbamoyl,
- aromatic carbocycle portion of "aromatic carbocycle”, “aromatic carbocyclyloxy”, “aromatic carbocyclylcarbonyl”, “aromatic carbocyclylcarbonyloxy”, “aromatic carbocyclyloxycarbonyl”, “aromatic carbocyclylcarbonylamino”, “aromatic carbocyclylamino”, “aromatic carbocyclylsulfanyl” and “aromatic carbocyclyl sulfonyl", “aromatic carbocyclylsulfamoyl” and “aromatic carbocyclylcarbamoyl” means the above "aromatic carbocyclyl".
- the term of "aromatic carbocyclyloxy” includes a group wherein an oxygen atom is substituted with the above "aromatic carbocyclyl”. Examples are phenyloxy and naphthyloxy.
- aromatic carbocyclylcarbonyl includes a group wherein a carbonyl group is substituted with the above “aromatic carbocyclyl”. Examples are phenylcarbonyl and naphthylcarbony.
- aromatic carbocyclylcarbonyloxy includes a group wherein a carbonyloxy group is substituted with the above “aromatic carbocyclyl”. Examples are phenylcarbonyloxy and naphthylcarbonyloxy.
- aromatic carbocyclyloxycarbonyl includes a group wherein a carbonyl group is substituted with the above “aromatic carbocyclyloxy”. Examples are phenyloxycarbonyl and naphthyloxycarbonyl.
- aromatic carbocyclylcarbonylamino includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of an amino group is replaced with the above “aromatic carbocyclylcarbonyl”. Examples are benzoylamino and naphthylcarbonylamino.
- aromatic carbocyclylamino includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of an amino group is replaced with the above “aromatic carbocyclyl”. Examples are phenylamino and naphthylamino.
- aromatic carbocyclylsulfanyl includes a group wherein a hydrogen atom attached to a sulfur atom of sulfanyl is replaced with the above “aromatic carbocyclyl”. Examples are phenylsulfanyl and naphthylsulfanyl.
- aromatic carbocyclylsulfonyl includes a group wherein a sulfonyl group is substituted with the above “aromatic carbocyclyl”. Examples are phenylsulfonyl and naphthylsulfonyl.
- aromatic carbocyclylsulfamoyl includes a group wherein one or two. hydrogen atoms attached to a nitrogen atom of a sulfamoyl group is replaced with the above “aromatic carbocyclyl”. Examples are phenylsulfamoyl and naphthylsulfamoyl.
- aromatic carbocyclylcarbamoyl includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of a carbamoyl group is replaced with the above “aromatic carbocyclyl”. Examples are phenylcarbamoyl and naphthylcarbamoyl.
- carbocyclylsulfamoyl and "non-aromatic carbocyclylcarbamoyl" means the above “non-aromatic carbocyclyl”.
- non-aromatic carbocyclyloxy includes a group wherein an oxygen atom is substituted with the above “non-aromatic carbocyclyl”. Examples are cyclopropyloxy, cyclohexyloxy and cyclohexenyloxy.
- non-aromatic carbocyclylcarbonyl includes a group wherein a carbonyl group is substituted with the above “non-aromatic carbocyclyl”. Examples are cyclopropylcarbonyl, cyclohexylcarbonyl and cyclohexenylcarbonyl.
- non-aromatic carbocyclylcarbonyloxy includes a group wherein a carbonyloxy group is substituted with the above “non-aromatic carbocyclyl”.
- non-aromatic carbocyclyloxycarbonyl includes a group wherein a carbonyl group is substituted with the above “non-aromatic carbocyclyloxy”.
- Examples are cyclopropyloxycarbonyl, cyclohexyloxycarbonyl and
- non-aromatic carbocyclylcarbonylamino includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of an amino group is replaced with the above “non-aromatic carbocyclylcarbonyl”. Examples are cyclopropylcarbonylamino, cyclohexylcarbonylamino and cyclohexenylcarbonylamino.
- non-aromatic carbocyclylamino includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of an amino group is replaced with the above “non-aromatic carbocyclyl”. Examples are cyclopropylamino, cyclohexylamino and cyclohexenylamino.
- non-aromatic carbocyclylsulfanyl includes a group wherein a hydrogen atom attached to a sulfur atom of a sulfanyl is replaced with the above “non-aromatic carbocyclyl”. Examples are cyclopropylsulfanyl, cyclohexylsulfanyl and cyclohexenylsulfanyl.
- non-aromatic carbocyclylsulfonyl includes a group wherein a sulfonyl group is substituted with the above "non-aromatic carbocyclyl”. Examples are cyclopropylsulfonyl, cyclohexylsulfonyl and cyclohexenylsulfonyl.
- non-aromatic carbocyclylsulfamoyl includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of a sulfamoyl group is replaced with the above “non-aromatic carbocyclyl”. Examples are
- non-aromatic carbocyclylcarbamoyl includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of a carbamoyl group is replaced with the above “non-aromatic carbocyclyl”. Examples are
- heterocyclyloxycarbonyl means the above "aromatic heterocyclyl”.
- aromatic heterocyclyloxy includes a group wherein an oxygen atom is substituted with the above “aromatic heterocyclyl”. Examples are pyridyloxy and oxazolyloxy.
- aromatic heterocyclylcarbonyl includes a group wherein a carbonyl group is substituted with the above “aromatic heterocyclyl”. Examples are pyridylcarbonyl and oxazolylcarbonyl.
- aromatic heterocyclylcarbonyloxy includes a group wherein a carbonyloxy group is substituted with the above “aromatic heterocyclyl”. Examples are pyridylcarbonyloxy and oxazolylcarbonyloxy. ,
- aromatic heterocyclyloxycarbonyl includes a group wherein a carbonyl group is substituted with the above "aromatic heterocyclyloxy”. Examples are pyridyloxycarbonyl and oxazolyloxycarbonyl.
- aromatic heterocyclylcarbonylamino includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of an amino group is replaced with the above “aromatic heterocyclylcarbonyl”. Examples are
- aromatic heterocyclylamino includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of an amino group is replaced with the above “aromatic heterocyclyl”. Examples are pyridylamino and oxazolylamino.
- aromatic heterbcyclylsulfanyl includes a group wherein a hydrogen atom attached to a sulfur atom of sulfanyl is replaced with the above “aromatic heterocyclyl”. Examples are pyridylsulfanyl and oxazolylsulfanyl.
- aromatic heterocyclylsulfonyl includes a group wherein a sulfonyl group is substituted with the above “aromatic heterocyclyl”. Examples are pyridylsulfonyl and oxazolylsulfonyl.
- aromatic heterocyclylsulfamoyl includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of a sulfamoyl group is replaced with the above “aromatic heterocyclyl”. Examples are pyridylsulfamoyl and oxazolylsulfamoyl.
- aromatic heterocyclylcarbamoyl includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of a carbamoyl group is replaced with the above “aromatic heterocyclyl”. Examples are pyridylcarbamoyl and oxazolylcarbamoyl.
- non-aromatic heterocyclyl portion of "non-aromatic heterocyclyloxy", “non-aromatic heterocyclylcarbonyl”, “non-aromatic heterocyclylcarbonyloxy", “non- aromatic heterocyclyloxycarbonyl", “non-aromatic heterocyclylcarbonylamino", “non- aromatic heterocyclylamino”, “non-aromatic heterocyclylsulfanyl", “non-aromatic heterocyclylsulfonyl", “non-aromatic heterocyclylsulfamoyl” and “non-aromatic heterocyclylcarbamoyl" means the above “non-aromatic heterocyclyl”.
- non-aromatic heterocyclyloxy includes a group wherein an oxygen atom is substituted with the above “non-aromatic heterocyclyl”.
- Examples are piperidinyloxy and tetrahydrofuryloxy.
- non-aromatic heterocyclylcarbonyl includes a group wherein a carbonyl group is substituted with the above “non-aromatic heterocyclyl”. Examples are piperidinylcarbonyl and tetrahydrofurylcarbonyl.
- non-aromatic heterocyclylcarbonyloxy includes a group wherein a carbonyloxy group is substituted with the above "non-aromatic
- heterocyclyl examples are piperidinylcarbonyloxy and tetrahydrofurylcarbonyloxy
- non-aromatic heterocyclyloxycarbonyl includes a group wherein a carbonyl group is substituted with the above "non-aromatic
- heterocyclyloxy examples are piperidinyloxycarbonyl and
- non-aromatic heterocyclylcarbonylamino includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of an amino group is replaced with the above “non-aromatic heterocyclylcarbonyl”. Examples are pipieidinylcarbonylamino and tetrahydrofurylcarbonylamino.
- non-aromatic heterocyclylamino includes a group wherein r one or two hydrogen atoms attached to a nitrogen atom of an amino group is replaced with the above “non-aromatic heterocyclyl”. Examples are piperidinylamino and tetrahydrofurylamino.
- non-aromatic heterocyclylsulfanyl includes a group wherein a hydrogen atom attached to a sulfur atom of sulfanyl is replaced with the above “non- aromatic heterocyclyl”. Examples are piperidinylsulfanyl and
- non-aromatic heterocyclylsulfonyl includes a group wherein a sulfonyl group is substituted with the above “non-aromatic heterocyclyl”.
- Examples are piperidinylsulfonyl and tetrahydrofurylsulfonyl.
- non-aromatic heterocyclylsulfamoyl includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of a sulfamoyl group is replaced with the above “non-aromatic heterocyclyl”. Examples are
- non-aromatic heterocyclylcarbamoyl includes a group wherein one or two hydrogen atoms attached to a nitrogen atom of a carbamoyl group is replaced with the above “non-aromatic heterocyclyl”. Examples are
- substituted or unsubstituted alkylene substituted or unsubstituted alkenylene
- substituted or unsubstituted alkynylene substituted or unsubstituted alkyloxy
- Substituent halogen, hydroxy, carboxy, amino, imino, hydroxyamino, hydroxyimino, formyl, formyloxy, carbamoyl, sulfamoyl, sulfanyl, sulfino, sulfo, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, cyano, nitro, nitroso, azide, hydrazino, ureido, amidino, guanidino, trialkylsilyl, alkyloxy, alkenyloxy, alkynyloxy, haloalkyloxy, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, monoalkylamino, dialkylamino, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl,
- alkylimino alkenylimino, alkynylimino, alkylcarbonylimino, alkenylcarbonylimino, alkynylcarbonylimino, alkyloxyimino, alkenyloxyimino, alkynyloxyimino, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkyloxycarbonyl, alkenyloxycarbonyl, alkynylcarbonyloxycarbonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylsulfanyl,
- heterocyclyloxycarbonyl aromatic carbocyclyl alkyloxy, non-aromatic carbocyclyl alkyloxy, aromatic heterocyclyl alkyloxy, non-aromatic heterocyclyl alkyloxy, aromatic carbocyclyl alkyloxycarbonyl, non-aromatic carbocyclyl alkyloxycarbonyl, aromatic heterocyclyl alkyloxycarbonyl, non-aromatic heterocyclyl alkyloxycarbonyl, aromatic carbocyclyl alkylamino, non-aromatic carbocyclyl alkylamino, aromatic heterocyclyl alkylamino, non-aromatic heterocyclyl alkylamino, aromatic
- carbocyclylsulfanyl non-aromatic carbocyclylsulfanyl, aromatic heterocyclylsulfanyl, non-aromatic heterocyclylsulfanyl, aromatic carbocyclylsulfonyl, non-aromatic carbocyclylsulfonyl, aromatic heterocyclylsulfonyl, and non-aromatic ,
- substituents of "substituted or unsubstituted alkyl" are one or more groups selected from the following substituent group a.
- the substituent group a is a group consisting of halogen, hydroxy, alkyloxy, haloalkyloxy, hydroxyalkyloxy, alkyloxyalkyloxy, formyl, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, aromatic carbocyclylcarbonyl , non-aromatic carbocyclylcarbonyl , aromatic heterocyclylcarbonyl , non-aromatic
- heterocyclylcarbonyl alkylcarbonyloxy, alkenylcarbonyloxy, aromatic
- heterocyclylcarbonyloxy non-aromatic heterocyclylcarbonyloxy, carboxy
- alkyloxycarbonyl amino, monoalkylcarbonylamino, dialkylcarbonylamino,
- dialkylsulfamoyl alkylsulfinyl, alkylsulfonyl, monoalkylsulfonylamino
- dialkylsulfonylamino alkylsulfonylalkylamino, alkylsulfonylimino
- substituents of "substituted or unsubstituted alkyl" are, for example, halogen, hydroxy and the like.
- substituted or unsubstituted alkenylene "substituted or unsubstituted alkynylene", “substituted or unsubstituted alkyloxy", "substituted or unsubstituted alkenyl” and “substituted or unsubstituted alkynyl” are one or more Selected from the above substituent group a. Specific examples are halogen, hydroxy and the like.
- substituents of "substituted or unsubstituted amino" are one or two selected from alkyl, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, aromatic carbocyclylcarbonyl , non-aromatic carbocyclylcarbonyl, aromatic
- heterocyclylcarbonyl non-aromatic heterocyclylcarbonyl , hydroxy, alkyloxy, alkyloxycarbonyl, aromatic carbocyclyl, non-aromatic carbocyclyl, aromatic
- heterocyclyl and non-aromatic heterocyclyl and the like.
- Specific examples are alkyl, alkylcarbonyl and the like.
- carbocycle "cycloalkyl", “aromatic heterocycle” and “non-aromatic heterocycle” of "substituted or unsubstituted aromatic carbocyclyl", “substituted or unsubstituted non-aromatic carbocyclyl", “substituted or unsubstituted cycloalkyl”, “substituted or unsubstituted aromatic heterocyclyl", and “substituted or unsubstituted non- aromatic heterocyclyl” include the group as follows. One or more atoms at any possible position(s) on each ring can be substituted with one or more substituents selected from the following group.
- Substituent- halogen hydroxy, carboxy, amino, imino, hydroxyamino, hydroxyimino, formyl, formyloxy, carbamoyl, sulfamoyl, sulfanyl, sulfino, sulfo, thioformyl, thiocarboxy, dithiocarbpxy, thiocarbamoyl, cyano, nitro, nitroso, azide, hydrazino, ureido, amidino, guanidino, trialkylsilyl, alkyl, alkenyl, alkynyl, haloalkyl, alkyloxy, alkenyloxy, alkynyloxy, haloalkyloxy, alkyloxyalkyl, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, monoalkylamino, dialkylamin
- alkynylimino alkylcarbonylimino, alkenylcarbonylimino, alkynylcarbonylimino, alkyloxyimino, alkenyloxyimino, alkynyloxyimino, alkylcarbonyloxy,
- carbocyclyloxy non-aromatic carbocyclyloxy, aromatic heterocyclyloxy, non-aromatic heterocyclyloxy, aromatic carbocyclylcarbonyl , non-aromatic carbocyclylcarbonyl, aromatic heterocyclylcarbonyl, non-aromatic heterocyclylcarbonyl, aromatic carbocyclyloxycarbonyl, non-aromatic carbocyclyloxycarbonyl, aromatic carbocyclyloxycarbonyl, non-aromatic carbocyclyloxycarbonyl, aromatic
- heterocyclyloxycarbonyl non-aromatic heterocyclyloxycarbonyl, aromatic
- carbocyclylalkyl non-aromatic carbocyclylalkyl , aromatic heterocyclylalkyl, non- aromatic hreterocyclylalkyl, aromatic carbocyclylalkyloxy, non-aromatic
- heterocyclylalkyloxy aromatic carbocyclylalkyloxycarbonyl, non-aromatic carbocyclylalkyloxy carbonyl, aromatic heterocyclylalkyloxycarbonyl, non-aromatic heterocyclylalkyloxycarbonyl, aromatic carbocyclylalkyloxyalkyl, non-aromatic carbocyclylalkyloxyalkyl, aromatic heterocyclylalkyloxyalkyl, non-aromatic
- heterocyclylalkyioxyalkyl aromatic carbocyclylalkylamino, non-aromatic
- heterocyclylalkylamino aromatic carbocyclylsulfanyl, non-aromatic
- carbocyclylsulfanyl aromatic heterocyclylsulfanyl, non-aromatic heterocyclylsulfanyl, non-aromatic carbocyclylsulfonyl, aromatic carbocyclylsulfonyl, aromatic
- heterocyclylsulfonyl and non-aromatic heterocyclylsulfonyl.
- a "substituted or unsubstituted non-aromatic carbocyclyl” and “substituted or unsubstituted non-aromatic heterocyclyl” can be substituted with "oxo".
- a group wherein two hydrogen atoms attached to the same carbon atom are replaced with oxo as follows is included:
- heterocyclylcarbonyl non-aromatic heterocyclylcarbonyl, formyloxy, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, aromatic carbocyclylcarbonyloxy, non- aromatic carbocyclylcarbonyloxy, aromatic heterocyclic carbonyloxy, non-aromatic heterocyclic carbonyloxy, carboxy, alkyloxycarbonyl, carbamoyl, amino, cyano, monoalkylamino, dialkylamino and/or alkylsulfanyl; (b) unsubstituted alkyl or alkyl substituted with one or more groups selected from the substituent group a, hydroxyimino and alkyloxyimino,'
- heterocyclylalkyloxy substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;
- heterocyclylsulfanyl substituted with one or more substituents selected from the (bf) substituent group a, azide, alkyl and haloalkyl;
- heterocyclylsulfonyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;
- heterocyclylcarbamoyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;
- heterocyclylcarbamoyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;
- heterocyclyloxycarbonyl substituted with one or more substituents selected from the substituent group a, azide, alkyl and haloalkyl;
- unsubstituted benzene "substituted or unsubstituted aromatic heterocycle", “substituted or unsubstituted non-aromatic heterocycle” and “substituted or unsubstituted pyridine” may be substituted with one or more substituents selected from the above substituents.
- substituents of "substituted or unsubstituted aromatic carbocycle”, “substituted or unsubstituted non-aromatic carbocycle”, “substituted or unsubstituted benzene”, “substituted or unsubstituted aromatic heterocycle”, “substituted or unsubstituted non-aromatic heterocycle” and “substituted or unsubstituted pyridine" are one or more selected from
- alkynylsulfanyl substituted with one or more substituents selected from the substituent group a,
- alkyloxycarbonyl substituted with one or more substituents selected from the substituent group a, .
- non-aromatic carbocyclyl substituted with one or more substituents selected from the substituent group a, unsubstituted alkyl, and alkyl substituted with one or more substituents selected from the substituent group a;
- aromatic heterocyclyl substituted with one or more substituents selected from the substituent group a, unsubstituted alkyl, and alkyl substituted with one or more substituents selected from the substituent group a;
- non-aromatic heterocyclyl substituted with one or more substituents selected from the substituent group a, unsubstituted alkyl, and alkyl substituted with one or more substituents selected from the substituent group a;
- substituents are one or more selected from halogen, cyano, hydroxy, alkyl, haloalkyl, cycloalkylalkyl, alkyloxy, haloalkyloxy,
- alkyloxyalkyloxy cyanoalkyloxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkenyloxy, alkynyloxy, alkylsulfanyl, cyanoalkylsulfanyl, amino, monoalkylamino, dialkylamino, cycloalkylamino and cycloalkyl.
- substituents are one or more selected from halogen, cyano, alkyl, haloalkyl, alkyloxy and haloalkyloxy.
- substituents of ring A is halogen
- the substituents of "substituted or unsubstituted cycloalkyl" are one. or more selected from the substituent group a, unsubstituted alkyl and alkyl substituted with one or more substituents selected from the substituent group a.
- substituted or unsubstituted cycloalkyl is unsubstituted cycloalkyl.
- each R 5 , each R 6 , each R 7 may be the same or different.
- R 1 is alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl or cycloalkyl (hereinafter referred to as R l l).
- R 1 is alkyl, haloalkyl alkynyl or cycloalkyl (hereinafter referred to as R12).
- R 1 is haloalkyl (hereinafter referred to as R 13).
- R 1 is alkynyl (hereinafter referred to as R14).
- R 1 is cycloalkyl (hereinafter referred to as R15).
- R 1 is alkyl (hereinafter referred to as R16).
- R 1 is CH2F, CHF2, or CF 3 (hereinafter referred to as R17).
- R 1 is CH2F or CHF2 (hereinafter referred to as R18).
- R 4 is hydrogen (hereinafter referred to as R4l).
- R 4 is halogen (hereinafter referred to as R42).
- R 2a , R 2b , R 3a , R3b ; R3c an d R3d are hydrogen (provided that R3c and R 3d are absence in the compound of the above formulas (IA), (IN) and (10), and R 3b and R 3d are absence in the compounds of formulas (IC), (IE), (IG), (II), (IK) and (IM).
- R231 refers to as R231.
- R 2a , R 2b , R 3a , R 3c and R 3d are hydrogen, and R 3b is halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, cyano or substituted or unsubstituted cycloalkyl (provided that R 3c and R 3d are absence in the compound of the above formulas (IA), (IN) and (IO), and R 3b and R 3d are absence in formulas (IC), (IE), (IG), (II), (IK) and (IM).
- R232 is halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, cyano or substituted or unsubstituted cycloalkyl
- R 2a , R 2b , R 3c and R 3 are hydrogen and, both of R 3a and R 3b are alkyl
- R 3c and R 3d are absence in the compound of the above formulas (IA), (IN) and (10), and R 3b and R 3d are absence in the compound of formulas of (IC), (IE), (IG), (II), (IK) and (IM) Hereinafter referred to as R233).
- At least one of the existing R 2a , R 2b , R 3a , R b , R 3c and R 3d is halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, cyano or substituted or unsubstituted cycloalkyl (provided that R 3c and R 3d are absence in the compound of formulas (IA), (IN) and (10), and R 3b and R 3d are absence in formulas (IC), (IE), (IG), (II), (IK) and (IM).
- R234 is halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, cyano or substituted or unsubstituted cycloalkyl (provided that R 3c and R 3d are absence in the compound of formulas (IA), (IN) and (10), and R 3b and R 3d are absence in formulas (IC), (IE), (IG),
- At least one of the existing R 2a , R 2b , R a , R 3b , R 3c and R 3d is halogen or substituted or unsubstituted alkyl (provided that R 3c and R 3d are absence in the compound of formulas (IA), (IN) and (10), and R 3b and R 3d are absence in the compounds of formulas (IC), (IE), (IG), (II), (IK) and (IM).
- R235 halogen or substituted or unsubstituted alkyl
- At least one of the existing R 2a , R 2b , R 3a , R 3b , R3 and R 3d is substituted or unsubstituted alkyl wherein the substituents are selected from one or more substituents selected from halogen and hydroxy (provided that R 3c and R 3d are absence in the compound of formulas (IA), (IN) and (10), and R 3b and R 3d are absence in the compounds of formulas (IC), (IE), (IG), (II), (IK) and (IM).
- R236 is substituted or unsubstituted alkyl wherein the substituents are selected from one or more substituents selected from halogen and hydroxy
- At least one of the existing R 2 , R 2b , R 3a , R 3 , R 3c and R 3d is substituted or unsubstituted alkyl wherein the substituents are selected from one or more substituents selected from halogen and the others of the existing R 2a , R 2b , R 3a , R 3b , R 3c and R 3d are hydrogen, halogen or alkyloxy (provided that R 3c and R 3d are absence in the compound of formulas (IA), (IN) and (10), and R 3b and R 3d are absence in the compounds of formulas (IC), (IE), (IG), (II), (IK) and (IM).
- R237 whereinafter referred to as R237).
- R 2a and R 2b is halogen and the other is hydrogen
- one of R 3a , R 3b , R 3c and R 3d is haloalkyl and the others are hydrogen (provided that R 3c are R 3d are absence in the compound of the formula (IA), (IN) and (10), and R 3b and R 3d are absence in the compounds of the formulas (IC), (IE), (IG), (II), (IK) and (IM).
- R 2a and R 2b is halogen or alkyloxy and the other is hydrogen
- one of R 3a , R3b j R3c and R 3d is haloalkyl and the others are hydrogen (provided that R 3c and R 3d are absence in the compound of formulas (IA), (IN) and (10), and R 3b and R 3d are absence in the compounds of formulas (IC), (IE), (IG), (II), (IK) and (IM).
- R239 Hereinafter referred to as R239).
- R 2a and R 2b is halogen or alkyloxy and the other is hydrogen
- one of R 3a and R 3b is CH2F or CHF2 and the other is hydrogen
- R 3c and R 3d are hydrogen (provided that R 3c and R 3d are absence in the compound of formulas (IA), (IN) and (10)
- R b and R 3d are absence in the compounds of formulas (IC), (IE), (IG), (II), (IK) and (IM).
- R2310 is halogen or alkyloxy and the other is hydrogen
- one of R 3a and R 3b is CH2F or CHF2 and the other is hydrogen
- R 3c and R 3d are hydrogen (provided that R 3c and R 3d are absence in the compound of formulas (IA), (IN) and (10)
- R b and R 3d are absence in the compounds of formulas (IC), (IE), (IG), (II), (IK) and (IM).
- R2310 is referred to as
- Both of R 2a and R 2b are hydrogen, one of R 3a , R b , R c and R 3 is haloalkyl and the others are hydrogen (provided that R 3c and R 3d are absence in the compound of formulas (IA), (IN) and (10), and R 3b and R 3d are absence in the compounds of formulas (IC), (IE), (IG), (II), (IK) and (IM).
- R2311 are hydrogen
- R 3c and R 3d are absence in the compound of formulas (IA), (IN) and (10)
- R 3b and R 3d are absence in the compounds of formulas (IC), (IE), (IG), (II), (IK) and (IM).
- R 2a , R 2b , R 3b , R 3c , R 3d , R 5 , R 6 , R7, n, m and p are the same as defined above (hereinafter referred to as R2312).
- R 2a , R 2b , R 3b , R 5 , R 6 , n and m are the same as defined above(hereinafter referred to as R2313).
- Ring B is a substituted or unsubstituted aromatic carbocycle, a substituted or unsubstituted non-aromatic carbocycle, a substituted or unsubstituted aromatic heterocycle or a substituted or unsubstituted non-aromatic heterocycle (hereinafter referred to as B l).
- Ring B is a substituted or unsubstituted aromatic heterocycle or a
- Ring B is a substituted or unsubstituted aromatic heterocycle (hereinafter referred to as B3).
- Ring B is substituted or unsubstituted pyridine, substituted or
- Ring B is a group of the following formula (hereinafter referred to as B5): rmula 54]
- R B6 is halogen or cyano
- R B7 is hydrogen, substituted or unsubstituted alkyl, halogen, hydroxy, substituted or unsubstituted amino or substituted or unsubstituted cycloalkyl.
- Ring B is a group of the following formula (hereinafter referred to as B6). rmula 55]
- R B 1 is halogen or cyano
- R B2 is substituted or unsubstituted alkyl, halogen, hydroxy, substituted or unsubstituted amino or substituted or
- Ring B s a group of the following formula (hereinafter referred to as B7).
- R B 1 is halogen or cyano
- R B2 is substituted or unsubstituted alkyl
- Ring B s a group of the following formula (hereinafter referred to as B8). [Chemical Formula 57]
- R B1 is cyano
- R B2 is alkyl
- ring B is a group of the following formula (hereinafter referred to as B9). [Chemical Formula 58]
- R B3 is halogen
- ring B is a group of the following formula (hereinafter referred to as B IO). [Chemical Formula 59]
- R B3 is cyano
- Ring B is a group of the following formula (hereinafter referred to as B l l). rmula 60]
- R B4 is substituted or unsubstituted alkyl or substituted or unsubstituted alkyloxy, and R B5 is hydrogen or substituted or unsubstituted amino.
- Ring B is a group of the following formula (hereinafter referred to as B 12) rmula 61]
- R B4 is substituted or unsubstituted alkyloxy and R B5 is hydrogen or substituted or unsubstituted amino.
- Ring B is a group of the following formula (hereinafter referred to as B 13). [Chemical Formula 62] wherein R B4 is alkyloxy or haloalkyloxy.
- Ring B is pyridine, pyrimidine, pyrazine,, oxazole, thiazole, pyrazole, benzene, benzoxazole or benzothiazole wherein each ring is optionally substituted with one or more substituents selected from the following groups (hereinafter referred to as B 14):
- alkyl substituted with one or more substituents selected from the substituent group a;
- alkynyl substituted with one or more substituents selected from the substituent group a;
- alkynylsulfanyl substituted with one or more substituents selected from the substituent group a,' - unsubstituted alkylsulfanyl;
- alkynylsulfanyl substituted with one or more substituents selected from the substituent group a, '
- dialkylcarbamoyl substituted with one or more substituents selected from the substituent group a;
- heterocyclyl substituted with one or more substituents selected from the substituent groupa, alkyl and haloalkyl;
- Ring B is pyridine, pyrimidine, pyrazine, oxazole, thiazole, pyrazole, benzene, benzoxazole or benzothiazole wherein each ring is optionally substituted with one or more substituents selected from the following groups (hereinafter referred to as B 15):
- halogen cyano, hydroxy, alkyl, haloalkyl, cycloalkylalkyl, alkyloxy, haloalkyloxy, alkyloxyalkyloxy, cyanoalkyloxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkenyloxy, alkynyloxy, alkylsulfanyl, cyanoalkylsulfanyl, amino, monoalkylamino, dialkylamino, cycloalkylamino and cycloalkyl.
- Ring B is pyridine, pyrazine, oxazole, thiazole, pyrazole, benzoxazole or benzothiazole wherein each ring is optionally substituted with one or more substituents selected from the following groups (hereinafter referred to as B 16).
- B 16 halogen, cyano, hydroxy, alkyl, haloalkyl, cycloalkylalkyl, alkyloxy, haloalkyloxy, alkenyl, haloalkenyl, alkynyl, haloalkynyl, amino, monoalkylamino, dialkylamino, cycloalkylamino and cycloalkyl.
- Ring B is pyridine or pyrazine wherein each ring is optionally substituted with one or more substituents selected from the following groups (hereinafter referred to as B 17).
- halogen cyano, hydroxy, alkyl, haloalkyl, cycloalkylalkyl, alkyloxy, haloalkyloxy, . alkenyl, haloalkenyl, alkynyl, haloalkynyl, amino, monoalkylamino, dialkylamino, cycloalkylamino and cycloalkyl. .
- Ring B is a group of the following formula (hereinafter referred to as B l8): rmula 63]
- R B 1 is cyano and R B2 is (i) hydroxy, (ii) alkyl optionally substituted with one or more substituents selected from the substituent group a, (iii) alkyloxy, (iv) alkynyl, (v) monoalkylamino, (vi) dialkylamino, (vii) cycloalkylamino or (viii) cycloalkyl.
- Ring B is a group of the following formula (hereinafter referred to as B 19). [Chemical Formula 64]
- R B1 is cyano
- R B2 is hydroxy, alkyl, haloalkyl, cycloalkylalkyl, alkyloxy, alkynyl, monoalkylamino, dialkylamino or cycloalkyl.
- Ring B is a group of the following formula (hereinafter referred to as B20).
- R B3 is alkyl, haloalkyl or haloalkyloxy and R B4 is hydrogen, hydroxy, amino, monoalkylamino, dialkylamino or cycloalkylamino.
- Ring B is a group of the following formula (hereinafter referred to as B2 l). rmula 66]
- R B3 is alkyl, haloalkyl or haloalkyloxy
- R B4 is hydroxy, amino, monoalkylamino, dialkylamino or cycloalkylamino.
- Ring A is a substituted or unsubstituted aromatic carbocycle or a
- Al substituted or unsubstituted aromatic heterocycle
- Ring A is substituted or unsubstituted benzene, substituted or
- unsubstituted pyridine substituted or unsubstituted pyrimidine, substituted or unsubstituted pyrazine, substituted or unsubstituted oxazole, substituted or unsubstituted thiazole, substituted or unsubstituted pyrazole, substituted or unsubstituted benzoxazole or substituted or unsubstituted benzothiazole
- A2 (hereinafter referred to as A2).
- Ring A is substituted or unsubstituted benzene or substituted or
- Ring A is unsubstituted pyridine or benzene optionally substituted with halogen (hereinafter referred to as A4).
- Ring A is benzene optionally substituted with halogen (hereinafter referred to as A5). > ⁇ .
- R 1 , R 4 , R 2a , R 2b , R 3a , R 3b (Ri, R4 ; « R2a ; R2b ; 3a ; R 3b , R 3c and R 3d ") of the compounds of formula (IA) are as follows:
- At least one of the existing R 2a , R 2b , R 3a and R 3b is halogen or substituted or unsubstituted alkyl and
- the others are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, cyano or substituted or unsubstituted cycloalkyl, and
- R 5 is halogen or substituted or unsubstituted alkyl, n is an integer of 0 to 2, m is an integer of 1 or 2,
- At least one of the existing R 2a , R 2b , R 3a and R 3b is substituted alkyl and
- the others are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, cyano or substituted or unsubstituted cycloalkyl, and ,
- R 2a and R 3a together with the carbon atoms to which they are attached, may form !
- R 5 is halogen or substituted or unsubstituted alkyl, n is an integer of 0 to 2, m is an integer of 1 or 2,
- At least one of the existing R 3a and R 3b is halogen, or substituted or unsubstituted alkyl and
- the other is hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, cyano or substituted or unsubstituted cycloalkyl, and
- R 2a and R 3a attached to adjacent carbon atoms, together with the carbon atoms to - which they are attached, may form
- R 5 is halogen or substituted or unsubstituted alkyl
- n is an integer of 0 to 2
- m is an integer of 1 or 2
- R 1 , R 4 , R 2a , R 2b , R 3a , R 3b , R 3c and R 3d , ring B and ring A R 1 , R4, "R 2a , R 2b , R 3a , R b , R 3c and R 3d ", ring B, ring A) of the compounds of any of the formulas (I) and (IA) to (10), preferably (IA) or (IB), and preferably (IA), are as follows-
- R41,R2311,B5 A4),(R13,R41,R2311,B6,A4),(R13,R41,R2311,B7,A4),(R13,R41,R2311,B 8,A4),(R13 ) R41,R2311,B9 ) A4),(R13,R41,R2311,B10,A4),(R13,R41,R2311,B11,A4),(R13 ,R41,R2311,B12,A4),(R13,R41,R2311,B13,A4),(R13,R41,R2311,B14,A4),(R13,R41,R23 11,B15,A4),(R13,R41,R2311,B16,A4),(R13,R41,R2311,B17,A4),(R13,R41,R2311,B18,A 4),(R13,R41,R2311,B19,A4),(R13,
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/434,013 US9540359B2 (en) | 2012-10-24 | 2013-10-23 | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
| EP13848316.9A EP2912035A4 (en) | 2012-10-24 | 2013-10-23 | DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY |
| JP2015516335A JP2016501827A (ja) | 2012-10-24 | 2013-10-23 | Bace1阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体 |
| US15/272,031 US9758513B2 (en) | 2012-10-24 | 2016-09-21 | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012-234461 | 2012-10-24 | ||
| JP2012234461 | 2012-10-24 | ||
| JP2013-154451 | 2013-07-25 | ||
| JP2013154451 | 2013-07-25 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/434,013 A-371-Of-International US9540359B2 (en) | 2012-10-24 | 2013-10-23 | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
| US15/272,031 Division US9758513B2 (en) | 2012-10-24 | 2016-09-21 | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2014065434A1 true WO2014065434A1 (en) | 2014-05-01 |
Family
ID=50544799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2013/079472 Ceased WO2014065434A1 (en) | 2012-10-24 | 2013-10-23 | Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US9540359B2 (https=) |
| EP (1) | EP2912035A4 (https=) |
| JP (1) | JP2016501827A (https=) |
| WO (1) | WO2014065434A1 (https=) |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9085576B2 (en) | 2013-03-08 | 2015-07-21 | Amgen Inc. | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| WO2015156421A1 (en) | 2014-04-11 | 2015-10-15 | Shionogi & Co., Ltd. | Dihydrothiazine and dihydrooxazine derivatives having bace1 inhibitory activity |
| WO2016022724A1 (en) | 2014-08-08 | 2016-02-11 | Amgen Inc. | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| US9296734B2 (en) | 2013-03-01 | 2016-03-29 | Amgen Inc. | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| US9346797B1 (en) | 2014-11-10 | 2016-05-24 | H. Lundbeck A/S | 2-amino 6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors |
| US9353084B2 (en) | 2014-02-19 | 2016-05-31 | H. Lundbeck A/S | 2-amino 3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treatment of Alzheimer's disease |
| US9540359B2 (en) | 2012-10-24 | 2017-01-10 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
| WO2017061534A1 (en) | 2015-10-08 | 2017-04-13 | Shionogi & Co., Ltd. | Dihydrothiazine derivatives |
| US9650371B2 (en) | 2008-06-13 | 2017-05-16 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
| US9656974B2 (en) | 2009-12-11 | 2017-05-23 | Shionogi & Co., Ltd. | Oxazine derivatives |
| WO2017148878A1 (en) * | 2016-03-01 | 2017-09-08 | F. Hoffmann-La Roche Ag | Bace 1 inhibitors |
| WO2018112083A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Thiazine derivatives as beta-secretase inhibitors and methods of use |
| WO2018112094A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use |
| WO2018112086A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use |
| WO2018112081A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Oxazine derivatives as beta-secretase inhibitors and methods of use |
| WO2018112084A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use |
| US10004738B2 (en) | 2015-08-10 | 2018-06-26 | H. Lundbeck A/S | Combination treatment comprising administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines |
| US10011596B2 (en) | 2015-08-12 | 2018-07-03 | H. Lundbeck A/S | 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors |
| US10058540B2 (en) | 2014-11-10 | 2018-08-28 | H. Lundbeck A/S | 2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors |
| US10059669B2 (en) | 2014-11-10 | 2018-08-28 | H. Lundbeck A/S | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treating alzheimer's disease |
| JP2019031532A (ja) * | 2013-04-11 | 2019-02-28 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Bace1阻害剤 |
| US10246429B2 (en) | 2015-08-06 | 2019-04-02 | Amgen Inc. | Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| WO2019208693A1 (en) | 2018-04-27 | 2019-10-31 | Shionogi & Co., Ltd. | Tetrahydropyranooxazine derivatives having selective bace1 inhibitory activity |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111592557A (zh) * | 2020-05-09 | 2020-08-28 | 河北合佳医药科技集团股份有限公司 | 一种7-氨基-3-乙烯基头孢烷酸的一步法环保制备方法 |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007049532A1 (ja) * | 2005-10-25 | 2007-05-03 | Shionogi & Co., Ltd. | アミノジヒドロチアジン誘導体 |
| WO2011069934A1 (en) * | 2009-12-11 | 2011-06-16 | F. Hoffmann-La Roche Ag | 2-amino-5, 5-difluoro-5, 6-dihydro-4h-oxazines as bace 1 and/or bace 2 inhibitors |
| WO2011070029A1 (en) * | 2009-12-10 | 2011-06-16 | F. Hoffmann-La Roche Ag | Amino oxazine derivatives |
| WO2011071135A1 (ja) * | 2009-12-11 | 2011-06-16 | 塩野義製薬株式会社 | オキサジン誘導体 |
| WO2012107371A1 (en) * | 2011-02-08 | 2012-08-16 | F. Hoffmann-La Roche Ag | N-[3-(5-amino-3,3a,7,7a-tetrahydro-1h-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as bace1 and/or bace2 inhibitors |
| WO2012139993A1 (en) * | 2011-04-11 | 2012-10-18 | F. Hoffmann-La Roche Ag | 1,3 oxazines as bace1 and/or bace2 inhibitors |
| WO2012156284A1 (en) * | 2011-05-16 | 2012-11-22 | F. Hoffmann-La Roche Ag | 1,3-oxazines as bace1 and/or bace2 inhibitors |
| WO2012168164A1 (en) * | 2011-06-07 | 2012-12-13 | F. Hoffmann-La Roche Ag | Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors |
| WO2012168175A1 (en) * | 2011-06-07 | 2012-12-13 | F. Hoffmann-La Roche Ag | [1,3]oxazines |
| JP2012250933A (ja) * | 2011-06-03 | 2012-12-20 | Shionogi & Co Ltd | オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物 |
| WO2013027188A1 (en) * | 2011-08-25 | 2013-02-28 | Novartis Ag | 2 -amino-4 - (pyridin- 2 -yl) - 5, 6 -dihydro-4h- 1, 3 -oxazine derivatives and their use as bace-1 and/or bace - 2 inhibitors |
| WO2013041499A1 (en) * | 2011-09-21 | 2013-03-28 | F. Hoffmann-La Roche Ag | N-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexahydro-cyclopenta[e][1,3]oxazin-4-yl)-phenyl)-amides as bace1 inhibitors |
| WO2013110622A1 (en) * | 2012-01-26 | 2013-08-01 | F. Hoffmann-La Roche Ag | Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines |
| WO2013142613A1 (en) * | 2012-03-20 | 2013-09-26 | Elan Pharmaceuticals, Inc. | Spirocyclic dihydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof |
Family Cites Families (200)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3227713A (en) | 1966-01-04 | Azine derivatives | ||
| US3235551A (en) | 1966-02-15 | Novel derivatives of | ||
| US2899426A (en) | 1959-08-11 | Synthesis of l | ||
| JPH09504278A (ja) | 1944-06-01 | 1997-04-28 | ザ、ウェルカム、ファンデーション、リミテッド | Noシンターゼインヒビターとしての置換尿素およびイソチオ尿素誘導体 |
| US3115494A (en) | 1961-10-13 | 1963-12-24 | Mcneilab Inc | 2-amino-5, 6-dihydro-4ii-1, 3-oxazines and a process for their preparation |
| BE637923A (https=) | 1962-09-29 | |||
| US3636116A (en) | 1968-09-03 | 1972-01-18 | Dow Chemical Co | 1 2-substituted indene compounds |
| SU465792A3 (ru) | 1968-11-06 | 1975-03-30 | Хиноин Гиогисцер-Ес Вегиесцети Термекек Гиара Рт (Фирма) | Способ получени гетероциклических соединений |
| US3577428A (en) | 1969-04-14 | 1971-05-04 | Colgate Palmolive Co | 2-amino-4-aryloxyalkyl-4-alkyl-2-oxazolines |
| US3719674A (en) | 1971-02-08 | 1973-03-06 | Dow Chemical Co | 1,2-substituted indene compounds |
| DE2426653C3 (de) | 1974-06-01 | 1982-05-06 | Bayer Ag, 5090 Leverkusen | Derivate des 2-Amino-1,3-thiazins |
| DD140144A1 (de) | 1978-11-08 | 1980-02-13 | Horst Hartmann | Verfahren zur herstellung von p-aminophenylsubstituierten 2-amino-1,3-thiaziniumsalzen |
| US4311840A (en) | 1980-11-13 | 1982-01-19 | E. R. Squibb & Sons, Inc. | 2,3,6,7-Tetrahydro-2-thioxo-4H-oxazolo[3,2-a]-1,3,5 triazin-4-ones |
| JPS62120374A (ja) | 1985-11-20 | 1987-06-01 | Yoshitomi Pharmaceut Ind Ltd | 1,3−チアジンまたは1,3−オキサジン誘導体 |
| JPH0231792Y2 (https=) | 1986-01-21 | 1990-08-28 | ||
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| CA1332151C (en) | 1988-01-28 | 1994-09-27 | Roman Amrein | Use of a benzamide to treat cognitive disorder |
| US5236942A (en) | 1990-04-19 | 1993-08-17 | Merrell Dow Pharmaceuticals Inc. | 5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful in the treatment of Altzheimer's dementia |
| US5328915A (en) | 1992-09-17 | 1994-07-12 | E. I. Du Pont De Nemours And Company | Arthropodicidal amidrazone ureas |
| IL107771A0 (en) | 1992-11-27 | 1994-02-27 | Wellcome Found | Pharmaceutical compositions containing isothiourea derivatives certain such novel compounds and their preparation |
| GB9418912D0 (en) | 1994-09-20 | 1994-11-09 | Fisons Corp | Pharmaceutically active compounds |
| WO1996014842A1 (en) | 1994-11-15 | 1996-05-23 | Merck & Co., Inc. | Substituted heterocycles as inhibitors of nitric oxide synthase |
| DE4442116A1 (de) | 1994-11-25 | 1996-05-30 | Cassella Ag | 2-Amino-1,3-thiazine als Hemmstoffe der Stickstoffmonoxid-Synthase |
| WO1996018607A1 (en) | 1994-12-12 | 1996-06-20 | Chugai Seiyaku Kabushiki Kaisha | Aniline derivative having the effect of inhibiting nitrogen monoxide synthase |
| JPH08333258A (ja) | 1994-12-14 | 1996-12-17 | Japan Tobacco Inc | チアジン又はチアゼピン誘導体及びそれら化合物を含有してなる一酸化窒素合成酵素阻害剤 |
| DE4444930A1 (de) | 1994-12-16 | 1996-06-27 | Cassella Ag | 2-Amino-1,3-thiazepine und deren Verwendung als Hemmstoffe der Stickstoffmonoxid-Synthase |
| NZ309134A (en) | 1995-08-11 | 1999-09-29 | Pfizer | (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1- propranolmethanesulfonate trihydrate |
| JPH0967355A (ja) | 1995-08-31 | 1997-03-11 | Tokyo Tanabe Co Ltd | チアジン誘導体、チアゾール誘導体及びそれらの製造方法 |
| NO307879B1 (no) | 1995-09-18 | 2000-06-13 | Sankyo Co | Nye ureaderivater med ACAT-inhiberende aktivitet og farmasøytisk preparat inneholdende disse |
| NZ319673A (en) | 1995-10-17 | 2000-06-23 | Astra Pharma Prod | Quinazoline compounds for inflammatory disorders such rheumatoid arthritis or osteoarthritis |
| US6063789A (en) | 1996-04-13 | 2000-05-16 | Astra Pharmaceuticals, Ltd. | Aminoisoquinolines and aminotheinopyridine derivatives and their use as anti-inflammatory agents |
| US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
| US5952374A (en) | 1997-09-29 | 1999-09-14 | Protein Technologies International, Inc. | Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function |
| SE9703693D0 (sv) | 1997-10-10 | 1997-10-10 | Astra Pharma Prod | Novel combination |
| TW460460B (en) | 1997-11-04 | 2001-10-21 | Chugai Pharmaceutical Co Ltd | Heterocyclic compounds having NOS inhibitory activities |
| US6294695B1 (en) | 1998-03-26 | 2001-09-25 | Mount Sinai School Of Medicine Of The City University Of New York | Aminobenzoic acid derivatives having anti-tumorigenic activity methods of making and using the same |
| AUPP285898A0 (en) | 1998-04-07 | 1998-04-30 | Fujisawa Pharmaceutical Co., Ltd. | Amido derivatives |
| SE9802333D0 (sv) | 1998-06-29 | 1998-06-29 | Astra Pharma Prod | Novel combination |
| US7375125B2 (en) | 1999-08-04 | 2008-05-20 | Ore Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
| DE60040676D1 (de) | 1999-09-17 | 2008-12-11 | Millennium Pharm Inc | BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa |
| EP1328261A2 (en) | 2000-04-12 | 2003-07-23 | Minerva Biotechnologies Corporation | Treatment of neurodegenerative disease |
| CN1251671C (zh) | 2000-05-19 | 2006-04-19 | 武田药品工业株式会社 | β分泌酶抑制剂 |
| US6420566B2 (en) | 2000-06-09 | 2002-07-16 | Aventis Pharma S.A. | Pharmaceutical compositions containing a 4, 5-dihydro-1, 3-thiazol-2-ylamine derivative, novel derivatives and preparation thereof |
| US6713276B2 (en) | 2000-06-28 | 2004-03-30 | Scios, Inc. | Modulation of Aβ levels by β-secretase BACE2 |
| WO2002062766A2 (en) | 2001-02-07 | 2002-08-15 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
| WO2002088101A2 (en) | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of bace |
| US6562783B2 (en) | 2001-05-30 | 2003-05-13 | Neurologic, Inc. | Phosphinylmethyl and phosphorylmethyl succinic and glutauric acid analogs as β-secretase inhibitors |
| NZ533107A (en) | 2001-11-08 | 2007-04-27 | Upjohn Co | N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives |
| PT1450750E (pt) | 2001-11-09 | 2010-01-18 | Aventis Pharma Sa | Derivados de 2-amino-4-piridilmetil-tiazolina e sua utilização como inibidores da no-sintase induzível |
| MXPA04003766A (es) | 2001-11-09 | 2004-07-29 | Aventis Pharma Sa | Derivados de 2-amino-4-heteroariletil tiazolina y su utilizacion como inhibidores de no sintasa inducible. |
| DK1446393T3 (da) | 2001-11-09 | 2006-07-10 | Aventis Pharma Sa | Derivater af 2-amino-thiazolin og fremstilling heraf som inhibitorer af inducerbar NO-syntase |
| WO2003082191A2 (en) | 2002-03-28 | 2003-10-09 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
| WO2004000312A2 (de) | 2002-06-19 | 2003-12-31 | Solvay Pharmaceuticals Gmbh | Arzneimittel zur behandlung von eine inhibition oder aktivitätsverminderung von ph-wert-regulierenden bikarbonat-transporter-proteinen erfordernden erkrangungen |
| AU2003249983A1 (en) | 2002-07-18 | 2004-02-09 | Actelion Pharmaceuticals Ltd | Piperidines useful for the treatment of central nervous system disorders |
| WO2004014843A1 (ja) | 2002-08-09 | 2004-02-19 | Takeda Chemical Industries, Ltd. | 置換アミノ化合物およびその用途 |
| TW200502221A (en) | 2002-10-03 | 2005-01-16 | Astrazeneca Ab | Novel lactams and uses thereof |
| JP2004149429A (ja) | 2002-10-29 | 2004-05-27 | Takeda Chem Ind Ltd | インドール化合物およびその用途 |
| JP2006096665A (ja) | 2002-10-29 | 2006-04-13 | Ono Pharmaceut Co Ltd | 脊柱管狭窄症治療剤 |
| CA2505098A1 (en) | 2002-11-12 | 2004-05-27 | Merck & Co., Inc. | Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease |
| RU2252936C2 (ru) | 2002-12-05 | 2005-05-27 | Институт физиологически активных веществ РАН | S-замещенные n-1-[(гетеро)арил]алкил-n`-[(гетеро)арил]алкилизотиомочевины, способ их получения, фармацевтическая композиция, способ изучения глутаматэргической системы, способы лечения (варианты) |
| US7429603B2 (en) | 2003-04-25 | 2008-09-30 | 3-Dimensional Pharmaceuticals, Inc. | C-fms kinase inhibitors |
| GB0324498D0 (en) | 2003-07-21 | 2003-11-26 | Aventis Pharma Inc | Heterocyclic compounds as P2X7 ion channel blockers |
| JP2007525482A (ja) | 2003-10-07 | 2007-09-06 | レノビス, インコーポレイテッド | イオンチャネルリガンドとしてのアミド化合物およびその使用 |
| PT1699455E (pt) | 2003-12-15 | 2013-08-27 | Merck Sharp & Dohme | Inibidores de protease de aspartilo heterocíclicos |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| EP1702284A4 (en) | 2003-12-24 | 2012-09-05 | Halliburton Energy Serv Inc | INCORRECT ESTIMATION BY USING FLUID ANALYSIS MODELS |
| JP2007530696A (ja) | 2004-03-30 | 2007-11-01 | メルク エンド カムパニー インコーポレーテッド | アスパラギン酸プロテアーゼ阻害剤として有用な2−アミノチアゾール化合物 |
| CA2564751A1 (en) | 2004-04-30 | 2005-11-24 | Schering Corporation | Neuropeptide receptor modulators |
| CA2578600A1 (en) | 2004-06-16 | 2006-01-26 | Wyeth | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase |
| AU2005277283A1 (en) | 2004-08-23 | 2006-03-02 | Merck Sharp & Dohme Corp. | Fused triazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| WO2006029850A1 (en) | 2004-09-14 | 2006-03-23 | The Genetics Company, Inc. | Hydrazone derivatives and their use as beta secretase inhibitors |
| WO2006041405A1 (en) | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Substituted amino-pyrimidones and uses thereof |
| EP1802587A4 (en) | 2004-10-15 | 2010-02-17 | Astrazeneca Ab | SUBSTITUTED AMINO BINDINGS AND THEIR APPLICATIONS |
| EP1831170A4 (en) | 2004-12-14 | 2009-10-14 | Astrazeneca Ab | SUBSTITUTED AMINOPYRIDINES AND THEIR USE |
| KR20070107022A (ko) | 2005-01-07 | 2007-11-06 | 신타 파마슈티칼스 코프. | 염증 및 면역 관련 용도를 위한 화합물 |
| CA2593515A1 (en) | 2005-01-14 | 2006-07-20 | Wyeth | Amino-imidazolones for the inhibition of beta-secretase |
| WO2006088705A1 (en) | 2005-02-14 | 2006-08-24 | Wyeth | Terphenyl guanidines as [beta symbol] -secretase inhibitors |
| WO2006088694A1 (en) | 2005-02-14 | 2006-08-24 | Wyeth | SUBSTITUTED THIENYL AND FURYL ACYLGUANIDINES AS β-SECRETASE MODULATORS |
| EP1848692A1 (en) | 2005-02-14 | 2007-10-31 | Wyeth | AZOLYLACYLGUANIDINES AS ß-SECRETASE INHIBITORS |
| ES2400287T3 (es) | 2005-03-14 | 2013-04-08 | High Point Pharmaceuticals, Llc | Derivados de benzazol, composiciones y procedimientos de uso como inhibidores de beta-secretasa |
| RU2008100164A (ru) | 2005-06-14 | 2009-07-20 | Шеринг Корпорейшн (US) | Получение и применение соединений в качестве ингибиторов протеаз |
| JP5118029B2 (ja) | 2005-06-14 | 2013-01-16 | タイゲン バイオテクノロジー カンパニー,リミテッド | ピリミジン化合物 |
| JP2008543840A (ja) | 2005-06-14 | 2008-12-04 | シェーリング コーポレイション | アスパルチルプロテアーゼインヒビター |
| AU2006259609A1 (en) | 2005-06-14 | 2006-12-28 | Pharmacopeia, Inc. | Aspartyl protease inhibitors |
| US7273882B2 (en) | 2005-06-21 | 2007-09-25 | Bristol-Myers Squibb Company | Aminoacetamide acyl guanidines as β-secretase inhibitors |
| TW200738683A (en) | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
| WO2007005404A1 (en) | 2005-06-30 | 2007-01-11 | Wyeth | AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION |
| TW200730523A (en) | 2005-07-29 | 2007-08-16 | Wyeth Corp | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation |
| EP1928841A1 (en) | 2005-09-26 | 2008-06-11 | Wyeth a Corporation of the State of Delaware | Amino-5- ý4- (difluoromethoxy) phenyl¨-5-phenylimidazolone compounds as inhibitors of the beta-secretase (bace) |
| TW200804290A (en) | 2005-11-15 | 2008-01-16 | Astrazeneca Ab | Compounds and uses thereof |
| CN101360720A (zh) | 2005-11-15 | 2009-02-04 | 阿斯利康(瑞典)有限公司 | 新颖的2-氨基嘧啶酮衍生物及其用途 |
| WO2007058582A1 (en) | 2005-11-15 | 2007-05-24 | Astrazeneca Ab | Novel 2-aminopyrimidinone or 2-aminopyridinone derivatives and their use |
| TW200734311A (en) | 2005-11-21 | 2007-09-16 | Astrazeneca Ab | New compounds |
| JP2009520686A (ja) | 2005-11-21 | 2009-05-28 | アストラゼネカ・アクチエボラーグ | 新規な2−アミノ−イミダゾール−4−オン化合物並びに認知障害、アルツハイマー病、神経変性及び認知症の治療に使用する医薬の製造におけるその使用 |
| WO2007078813A2 (en) | 2005-12-19 | 2007-07-12 | Wyeth | 2-AMINO-5-PIPERIDINYLIMIDAZOLONE COMPOUNDS AND USE THEREOF FOR β-SECRETASE MODULATION |
| AR058381A1 (es) | 2005-12-19 | 2008-01-30 | Astrazeneca Ab | Compuestos derivados de 2-aminopiridin-4-onas y una composicion farmaceutica |
| PE20071025A1 (es) | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
| US7776882B2 (en) | 2006-02-06 | 2010-08-17 | Baxter Ellen W | 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE) |
| WO2007092854A2 (en) | 2006-02-06 | 2007-08-16 | Janssen Pharmaceutica N.V. | 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) |
| US20090099217A1 (en) | 2006-04-05 | 2009-04-16 | Astex Therapeutics Ltd. | 2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies |
| TW200808751A (en) | 2006-04-13 | 2008-02-16 | Astrazeneca Ab | New compounds |
| NZ572073A (en) | 2006-04-20 | 2011-09-30 | Janssen Pharmaceutica Nv | Heterocyclic compounds as inhibitors of c-fms kinase |
| KR20090015967A (ko) | 2006-06-12 | 2009-02-12 | 쉐링 코포레이션 | 헤테로사이클릭 아스파르틸 프로테아제 억제제 |
| EP2044061A2 (en) | 2006-07-20 | 2009-04-08 | Mehmet Kahraman | Benzothiophene inhibitors of rho kinase |
| TW200817406A (en) | 2006-08-17 | 2008-04-16 | Wyeth Corp | Imidazole amines as inhibitors of β-secretase |
| AU2007332754A1 (en) | 2006-12-12 | 2008-06-19 | Schering Corporation | Aspartyl protease inhibitors |
| CN101631779A (zh) | 2006-12-12 | 2010-01-20 | 先灵公司 | 含有三环系统的天冬氨酰蛋白酶抑制剂 |
| TW200831080A (en) | 2006-12-15 | 2008-08-01 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
| CA2676944C (en) | 2007-02-15 | 2016-01-19 | F. Hoffmann-La Roche Ag | 2-aminooxazolines as taar1 ligands |
| EP2147914B1 (en) | 2007-04-24 | 2014-06-04 | Shionogi&Co., Ltd. | Aminodihydrothiazine derivatives substituted with cyclic groups |
| EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| GB0713686D0 (en) | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| JP4846769B2 (ja) | 2007-07-30 | 2011-12-28 | 田辺三菱製薬株式会社 | 医薬組成物 |
| US9986911B2 (en) | 2007-10-19 | 2018-06-05 | Smiths Medical Asd, Inc. | Wireless telecommunications system adaptable for patient monitoring |
| WO2009064418A1 (en) | 2007-11-14 | 2009-05-22 | Amgen Inc. | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
| RU2476431C2 (ru) | 2008-01-18 | 2013-02-27 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Конденсированное производное аминодигидротиазина |
| US8076358B2 (en) | 2008-01-28 | 2011-12-13 | Janssen Pharmaceutica Nv | 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE) |
| ES2397682T3 (es) | 2008-01-29 | 2013-03-08 | Janssen Pharmaceutica Nv | Derivados de 2-amino-quinolina útiles como inhibidores de la beta-secretasa (BACE) |
| ES2475206T3 (es) | 2008-02-01 | 2014-07-10 | Takeda Pharmaceutical Company Limited | Derivados de oxima como inhibidores de HSP90 |
| AU2009216825A1 (en) | 2008-02-18 | 2009-08-27 | F. Hoffmann-La Roche Ag | 4, 5-dihydro-oxazol-2-yl amine derivatives |
| US8450331B2 (en) | 2008-04-22 | 2013-05-28 | Merck Sharp & Dohme Corp. | Thiophenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use |
| TWI431004B (zh) | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Bace抑制劑 |
| WO2009151098A1 (ja) | 2008-06-13 | 2009-12-17 | 塩野義製薬株式会社 | βセクレターゼ阻害作用を有する含硫黄複素環誘導体 |
| EP2318416B1 (en) | 2008-07-28 | 2013-09-04 | Eisai R&D Management Co., Ltd. | Spiroaminodihydrothiazine derivatives |
| WO2010013302A1 (ja) | 2008-07-28 | 2010-02-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スピロアミノジヒドロチアジン誘導体 |
| EP2312945A4 (en) | 2008-08-13 | 2012-05-09 | Merck Sharp & Dohme | PURE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER |
| US8685972B2 (en) | 2008-08-13 | 2014-04-01 | Merck Sharp & Dohme Corp. | Pyrimidine derivatives for treatment of alzheimer's disease |
| KR20110076965A (ko) | 2008-09-30 | 2011-07-06 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신규한 축합 아미노 디하이드로티아진 유도체 |
| CN102186841A (zh) | 2008-10-22 | 2011-09-14 | 盐野义制药株式会社 | 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物 |
| TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
| US20100125087A1 (en) | 2008-11-14 | 2010-05-20 | Astrazeneca Ab | New compounds 575 |
| US20100125081A1 (en) | 2008-11-14 | 2010-05-20 | Astrazeneca Ab | New compounds 574 |
| WO2010113848A1 (ja) | 2009-03-31 | 2010-10-07 | 塩野義製薬株式会社 | Bace1阻害作用を有するイソチオウレア誘導体またはイソウレア誘導体 |
| KR101123178B1 (ko) | 2009-04-09 | 2012-06-13 | (주)에스메디 | 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물 |
| CA2760946C (en) | 2009-05-07 | 2019-06-25 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for studying, imaging, and treating pain |
| US8461160B2 (en) | 2009-05-08 | 2013-06-11 | Hoffmann-La Roche, Inc. | Dihydropyrimidinones |
| AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
| GB0912777D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydropyrimidone derivatives |
| GB0912778D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
| UY32799A (es) | 2009-07-24 | 2011-02-28 | Novartis Ag | Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos |
| US8188079B2 (en) | 2009-08-19 | 2012-05-29 | Hoffman-La Roche Inc. | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines |
| US20110065695A1 (en) | 2009-09-11 | 2011-03-17 | Jeremy Beauchamp | Use of aminodihydrothiazines for the treatment or prevention of diabetes |
| EP2485590B1 (en) | 2009-10-08 | 2015-01-07 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| US8563543B2 (en) | 2009-10-08 | 2013-10-22 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| EP2485920B1 (en) | 2009-10-08 | 2016-04-27 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
| US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
| EP2500344A4 (en) | 2009-11-13 | 2013-05-01 | Shionogi & Co | AMINOTHIAZIN OR AMINOOXAZINE DERIVATIVES WITH AN AMINO TERMINATION |
| EP2509983B1 (en) | 2009-11-16 | 2014-09-17 | Merck Sharp & Dohme Corp. | FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY |
| EP2514747A4 (en) | 2009-12-09 | 2013-05-08 | Shionogi & Co | SUBSTITUTED AMINOTHIAZINE DERIVATIVE |
| JP5554346B2 (ja) | 2009-12-09 | 2014-07-23 | 塩野義製薬株式会社 | 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物 |
| EP2511269A4 (en) | 2009-12-11 | 2013-04-24 | Shionogi & Co | FUSED HETEROCYCLIC COMPOUND HAVING AN AMINO GROUP |
| US20120258961A1 (en) | 2009-12-24 | 2012-10-11 | Shionogi & Co., Ltd. | 4-amino-1,3-thiazine or oxazine derivative |
| WO2011080176A1 (en) | 2009-12-31 | 2011-07-07 | Novartis Ag | Pyrazine derivatives and their use in the treatment of neurological disorders |
| US8673894B2 (en) | 2010-05-07 | 2014-03-18 | Hoffmann-La Roche Inc. | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds |
| EA201291366A1 (ru) | 2010-06-09 | 2013-04-30 | Янссен Фармацевтика Нв | Производные 5-амино-3,6-дигидро-1h-пиразин-2-она в качестве ингибиторов бета-секретазы (bace) |
| KR101730937B1 (ko) | 2010-06-09 | 2017-04-27 | 얀센 파마슈티카 엔.브이. | 베타-세크레타아제(bace) 저해제로 유용한 5,6-디하이드로-2h-[1,4]옥사진-3-일-아민 유도체 |
| CN102985412A (zh) | 2010-06-28 | 2013-03-20 | 詹森药业有限公司 | 可用于治疗阿尔茨海默病及其它形式的痴呆的3-氨基-5,6-二氢-1h-吡嗪-2-酮衍生物 |
| PH12012500361A1 (en) | 2010-07-13 | 2012-01-19 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
| US8815881B2 (en) | 2010-08-09 | 2014-08-26 | Hoffmann-La Roche Inc. | 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds |
| US8609660B2 (en) | 2010-09-22 | 2013-12-17 | Janssen Pharmaceutica Nv | 4,7-dihydro-pyrazolo[1,5-a]pyrazin-6-ylamine derivatives useful as inhibitors of beta-secretase (BACE) |
| JP5816630B2 (ja) | 2010-10-29 | 2015-11-18 | 塩野義製薬株式会社 | ナフチリジン誘導体 |
| JP5766198B2 (ja) | 2010-10-29 | 2015-08-19 | 塩野義製薬株式会社 | 縮合アミノジヒドロピリミジン誘導体 |
| SG191097A1 (en) | 2010-12-22 | 2013-08-30 | Janssen Pharmaceutica Nv | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) |
| GB201100181D0 (en) | 2011-01-06 | 2011-02-23 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| US8524897B2 (en) | 2011-01-12 | 2013-09-03 | Novartis Ag | Crystalline oxazine derivative |
| CN103429589A (zh) | 2011-01-12 | 2013-12-04 | 诺瓦提斯公司 | 噁嗪衍生物及其在治疗神经障碍中的用途 |
| PT2663561E (pt) | 2011-01-13 | 2016-06-07 | Novartis Ag | Derivados heterocíclicos novos e sua utilização no tratamento de distúrbios neurológicos |
| MX2013008192A (es) | 2011-01-13 | 2013-12-16 | Novartis Ag | Inhibidores de bace-2 para tratamiento de transtornos metabolicos. |
| US9242943B2 (en) | 2011-01-18 | 2016-01-26 | Siena Biotech S.P.A. | 1,4 oxazines as BACE1 and/or BACE2 inhibitors |
| GB201101140D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| GB201101139D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| US8399459B2 (en) | 2011-02-02 | 2013-03-19 | Hoffmann-La Roche Inc. | 1,4 oxazines as BACE1 and/or BACE2 inhibitors |
| US20130040971A1 (en) | 2011-02-14 | 2013-02-14 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders |
| US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
| US8815841B2 (en) | 2011-02-18 | 2014-08-26 | Hoffmann-La Roche Inc. | 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors |
| JP5853033B2 (ja) | 2011-03-01 | 2016-02-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap | β−セクレターゼ(BACE)の阻害剤として有用な6,7−ジヒドロ−ピラゾロ[1,5−a]ピラジン−4−イルアミン誘導体 |
| US9067924B2 (en) | 2011-03-04 | 2015-06-30 | Hoffmann-La Roche Inc. | 1,4 thiazepines/sulfones as BACE1 and/or BACE2 inhibitors |
| EP2683721B1 (en) | 2011-03-09 | 2015-01-28 | Janssen Pharmaceutica N.V. | 3,4-DIHYDRO-PYRROLO[1,2-a]PYRAZIN-1-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) |
| US8748418B2 (en) | 2011-03-18 | 2014-06-10 | Hoffmann-La Roche Inc. | 1,4-oxazepines as BACE1 and/or BACE2 inhibitors |
| US8877744B2 (en) | 2011-04-04 | 2014-11-04 | Hoffmann-La Roche Inc. | 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors |
| TW201247635A (en) | 2011-04-26 | 2012-12-01 | Shionogi & Co | Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them |
| WO2012147762A1 (ja) | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | ピリジン誘導体およびそれを含有するbace1阻害剤 |
| WO2012162334A1 (en) | 2011-05-24 | 2012-11-29 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| US8604024B2 (en) | 2011-05-24 | 2013-12-10 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| US9079919B2 (en) | 2011-05-27 | 2015-07-14 | Hoffmann-La Roche Inc. | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors |
| UA111749C2 (uk) | 2011-12-05 | 2016-06-10 | Янссен Фармацевтика Нв | Похідні 6-дифторметил-5,6-дигідро-2h-[1,4]оксазин-3-аміну |
| ES2582473T3 (es) | 2011-12-06 | 2016-09-13 | Janssen Pharmaceutica, N.V. | Derivados de 5-(3-aminofenil)-5-alquil-5,6-dihidro-2H-[1,4]oxazin-3-amina para el tratamiento de trastornos en que está implicada la beta-secretasa |
| US8338413B1 (en) | 2012-03-07 | 2012-12-25 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
| CA2872181A1 (en) | 2012-06-26 | 2014-01-03 | F. Hoffmann-La Roche Ag | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors |
| WO2014010748A1 (en) | 2012-07-10 | 2014-01-16 | Shionogi & Co., Ltd. | Cyclopropane derivative having bace1 inhibiting activity |
| JP2014101354A (ja) | 2012-10-24 | 2014-06-05 | Shionogi & Co Ltd | Bace1阻害作用を有するオキサジン誘導体 |
| EP2912035A4 (en) | 2012-10-24 | 2016-06-15 | Shionogi & Co | DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY |
| JP2014101353A (ja) | 2012-10-26 | 2014-06-05 | Shionogi & Co Ltd | オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物 |
| WO2014098831A1 (en) | 2012-12-19 | 2014-06-26 | Bristol-Myers Squibb Company | 4,6-diarylaminothiazines as bace1 inhibitors and their use for the reduction of beta-amyloid production |
| CN104968660A (zh) | 2013-01-22 | 2015-10-07 | 霍夫曼-拉罗奇有限公司 | 作为bace1抑制剂的氟-[1,3]噁嗪类化合物 |
| CA2902212C (en) | 2013-03-01 | 2020-10-13 | Amgen Inc. | Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| AP2015008716A0 (en) | 2013-03-08 | 2015-09-30 | Amgen Inc | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| PE20151748A1 (es) | 2013-04-11 | 2015-12-02 | Hoffmann La Roche | Inhibidores de bace1 |
-
2013
- 2013-10-23 EP EP13848316.9A patent/EP2912035A4/en not_active Withdrawn
- 2013-10-23 US US14/434,013 patent/US9540359B2/en not_active Expired - Fee Related
- 2013-10-23 WO PCT/JP2013/079472 patent/WO2014065434A1/en not_active Ceased
- 2013-10-23 JP JP2015516335A patent/JP2016501827A/ja active Pending
-
2016
- 2016-09-21 US US15/272,031 patent/US9758513B2/en not_active Expired - Fee Related
Patent Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007049532A1 (ja) * | 2005-10-25 | 2007-05-03 | Shionogi & Co., Ltd. | アミノジヒドロチアジン誘導体 |
| WO2011070029A1 (en) * | 2009-12-10 | 2011-06-16 | F. Hoffmann-La Roche Ag | Amino oxazine derivatives |
| WO2011069934A1 (en) * | 2009-12-11 | 2011-06-16 | F. Hoffmann-La Roche Ag | 2-amino-5, 5-difluoro-5, 6-dihydro-4h-oxazines as bace 1 and/or bace 2 inhibitors |
| WO2011071135A1 (ja) * | 2009-12-11 | 2011-06-16 | 塩野義製薬株式会社 | オキサジン誘導体 |
| WO2012107371A1 (en) * | 2011-02-08 | 2012-08-16 | F. Hoffmann-La Roche Ag | N-[3-(5-amino-3,3a,7,7a-tetrahydro-1h-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as bace1 and/or bace2 inhibitors |
| WO2012139993A1 (en) * | 2011-04-11 | 2012-10-18 | F. Hoffmann-La Roche Ag | 1,3 oxazines as bace1 and/or bace2 inhibitors |
| WO2012156284A1 (en) * | 2011-05-16 | 2012-11-22 | F. Hoffmann-La Roche Ag | 1,3-oxazines as bace1 and/or bace2 inhibitors |
| JP2012250933A (ja) * | 2011-06-03 | 2012-12-20 | Shionogi & Co Ltd | オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物 |
| WO2012168164A1 (en) * | 2011-06-07 | 2012-12-13 | F. Hoffmann-La Roche Ag | Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors |
| WO2012168175A1 (en) * | 2011-06-07 | 2012-12-13 | F. Hoffmann-La Roche Ag | [1,3]oxazines |
| WO2013027188A1 (en) * | 2011-08-25 | 2013-02-28 | Novartis Ag | 2 -amino-4 - (pyridin- 2 -yl) - 5, 6 -dihydro-4h- 1, 3 -oxazine derivatives and their use as bace-1 and/or bace - 2 inhibitors |
| WO2013041499A1 (en) * | 2011-09-21 | 2013-03-28 | F. Hoffmann-La Roche Ag | N-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexahydro-cyclopenta[e][1,3]oxazin-4-yl)-phenyl)-amides as bace1 inhibitors |
| WO2013110622A1 (en) * | 2012-01-26 | 2013-08-01 | F. Hoffmann-La Roche Ag | Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines |
| WO2013142613A1 (en) * | 2012-03-20 | 2013-09-26 | Elan Pharmaceuticals, Inc. | Spirocyclic dihydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof |
Non-Patent Citations (3)
| Title |
|---|
| "[BETA]-SECRETASE (BACE1) INHIBITORS WITH HIGH IN VIVO EFFICACY SUITABLE FOR CLINICAL EVALUATION IN ALZHEIMER'S DISEASE", JOURNAL OF MEDICINAL CHEMISTRY, vol. 56, no. 10, 2013, pages 3980 - 3995, XP055113495 * |
| "BACE1 INHIBITORS: A HEAD GROUP SCAN ON A SERIES OF AMIDES", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 23, no. 14, 2013, pages 4239 - 4243, XP028573309 * |
| See also references of EP2912035A4 * |
Cited By (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9650371B2 (en) | 2008-06-13 | 2017-05-16 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
| EP2511268B2 (en) † | 2009-12-11 | 2021-02-17 | Shionogi & Co., Ltd. | Oxazine derivative |
| US9656974B2 (en) | 2009-12-11 | 2017-05-23 | Shionogi & Co., Ltd. | Oxazine derivatives |
| US9540359B2 (en) | 2012-10-24 | 2017-01-10 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
| US9758513B2 (en) | 2012-10-24 | 2017-09-12 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
| US9296734B2 (en) | 2013-03-01 | 2016-03-29 | Amgen Inc. | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| US9085576B2 (en) | 2013-03-08 | 2015-07-21 | Amgen Inc. | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| EP2964644B1 (en) * | 2013-03-08 | 2018-12-26 | Amgen, Inc. | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| JP2016510758A (ja) * | 2013-03-08 | 2016-04-11 | アムジエン・インコーポレーテツド | β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合1,3−オキサジン−2−アミン化合物、及び使用方法 |
| US9611261B2 (en) | 2013-03-08 | 2017-04-04 | Amgen Inc. | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| US11447478B2 (en) | 2013-04-11 | 2022-09-20 | Hoffmann-La Roche Inc. | BACE1 inhibitors |
| JP2019031532A (ja) * | 2013-04-11 | 2019-02-28 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Bace1阻害剤 |
| US9353084B2 (en) | 2014-02-19 | 2016-05-31 | H. Lundbeck A/S | 2-amino 3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treatment of Alzheimer's disease |
| CN106414431A (zh) * | 2014-04-11 | 2017-02-15 | 盐野义制药株式会社 | 具有bace1抑制作用的二氢噻嗪和二氢噁嗪衍生物 |
| WO2015156421A1 (en) | 2014-04-11 | 2015-10-15 | Shionogi & Co., Ltd. | Dihydrothiazine and dihydrooxazine derivatives having bace1 inhibitory activity |
| KR20160141849A (ko) | 2014-04-11 | 2016-12-09 | 시오노기세이야쿠가부시키가이샤 | Bace1 저해 작용을 갖는 디하이드로티아진 및 디하이드로옥사진 유도체 |
| JP2017523223A (ja) * | 2014-08-08 | 2017-08-17 | アムジエン・インコーポレーテツド | β−セクレターゼ阻害剤としてのシクロプロピル縮合チアジン−2−アミン化合物及び使用方法 |
| WO2016022724A1 (en) | 2014-08-08 | 2016-02-11 | Amgen Inc. | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| US9550762B2 (en) | 2014-08-08 | 2017-01-24 | Amgen, Inc. | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| US10603310B2 (en) | 2014-11-10 | 2020-03-31 | H. Lundbeck A/S | 2-amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors |
| US9346797B1 (en) | 2014-11-10 | 2016-05-24 | H. Lundbeck A/S | 2-amino 6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors |
| US10045974B2 (en) | 2014-11-10 | 2018-08-14 | H. Lundbeck A/S | 2-amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors |
| US10058540B2 (en) | 2014-11-10 | 2018-08-28 | H. Lundbeck A/S | 2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors |
| US10059669B2 (en) | 2014-11-10 | 2018-08-28 | H. Lundbeck A/S | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treating alzheimer's disease |
| US10246429B2 (en) | 2015-08-06 | 2019-04-02 | Amgen Inc. | Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| US10004738B2 (en) | 2015-08-10 | 2018-06-26 | H. Lundbeck A/S | Combination treatment comprising administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines |
| US10011596B2 (en) | 2015-08-12 | 2018-07-03 | H. Lundbeck A/S | 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors |
| WO2017061534A1 (en) | 2015-10-08 | 2017-04-13 | Shionogi & Co., Ltd. | Dihydrothiazine derivatives |
| CN108699051B (zh) * | 2016-03-01 | 2021-12-24 | 豪夫迈·罗氏有限公司 | Bace1抑制剂 |
| CN108699051A (zh) * | 2016-03-01 | 2018-10-23 | 豪夫迈·罗氏有限公司 | Bace1抑制剂 |
| WO2017148878A1 (en) * | 2016-03-01 | 2017-09-08 | F. Hoffmann-La Roche Ag | Bace 1 inhibitors |
| US10947223B2 (en) | 2016-12-15 | 2021-03-16 | Amgen Inc. | Substituted oxazines as beta-secretase inhibitors |
| WO2018112083A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Thiazine derivatives as beta-secretase inhibitors and methods of use |
| US10889579B2 (en) | 2016-12-15 | 2021-01-12 | Amgen Inc. | Thiazine derivatives as β-secretase inhibitors and methods of use |
| US10889581B2 (en) | 2016-12-15 | 2021-01-12 | Amgen Inc. | Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use |
| WO2018112094A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use |
| WO2018112086A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use |
| US11021493B2 (en) | 2016-12-15 | 2021-06-01 | Amgen Inc. | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use |
| WO2018112084A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use |
| WO2018112081A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Oxazine derivatives as beta-secretase inhibitors and methods of use |
| US11548903B2 (en) | 2016-12-15 | 2023-01-10 | Amgen Inc. | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use |
| WO2019208693A1 (en) | 2018-04-27 | 2019-10-31 | Shionogi & Co., Ltd. | Tetrahydropyranooxazine derivatives having selective bace1 inhibitory activity |
| KR20210003872A (ko) | 2018-04-27 | 2021-01-12 | 시오노기 앤드 컴파니, 리미티드 | 선택적 bace1 억제 활성을 갖는 테트라하이드로피라노옥사진 유도체 |
| US11629154B2 (en) | 2018-04-27 | 2023-04-18 | Shionogi & Co., Ltd. | Tetrahydropyranooxazine derivatives having selective BACE1 inhibitory activity |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2912035A1 (en) | 2015-09-02 |
| EP2912035A4 (en) | 2016-06-15 |
| US20150266865A1 (en) | 2015-09-24 |
| US20170008881A1 (en) | 2017-01-12 |
| US9540359B2 (en) | 2017-01-10 |
| US9758513B2 (en) | 2017-09-12 |
| JP2016501827A (ja) | 2016-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2014065434A1 (en) | Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity | |
| ES2672530T3 (es) | Amidas heterocíclicas como inhibidores de cinasas | |
| EP3129370A1 (en) | Dihydrothiazine and dihydrooxazine derivatives having bace1 inhibitory activity | |
| JP6725177B2 (ja) | 9員縮合環誘導体 | |
| JP2010526145A (ja) | [6,6]および[6,7]−二環式gpr119gタンパク質結合受容体アゴニスト | |
| US20210292283A1 (en) | 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same | |
| JPWO2017006953A1 (ja) | TrkA阻害活性を有する複素環誘導体 | |
| JPWO2015174511A1 (ja) | Hiv複製阻害作用を有する3環性複素環誘導体 | |
| JP7038460B2 (ja) | 二環性含窒素複素環誘導体およびそれらを含有する医薬組成物 | |
| WO2018079759A1 (ja) | TrkA阻害活性を有する縮合複素環および縮合炭素環誘導体 | |
| JP2014101354A (ja) | Bace1阻害作用を有するオキサジン誘導体 | |
| WO2015199206A1 (ja) | Trpv4阻害活性を有する6員環誘導体 | |
| WO2020009179A1 (en) | Fused heterocyclic derivatives having selective bace1 inhibitory activity | |
| JP2017071603A (ja) | ジヒドロチアジンまたはジヒドロオキサジン誘導体を含有する医薬組成物 | |
| WO2017061534A1 (en) | Dihydrothiazine derivatives | |
| JP2021075519A (ja) | 選択的bace1阻害活性を有するテトラヒドロピラノオキサジン誘導体を含有する医薬組成物 | |
| JP2018090574A (ja) | 含窒素3環性誘導体を含有する医薬組成物 | |
| EP3784674B1 (en) | Tetrahydropyranooxazine derivatives having selective bace1 inhibitory activity | |
| TW202409011A (zh) | 人類呼吸道融合病毒及間質肺病毒抑制劑 | |
| JP6692113B2 (ja) | 6員複素環誘導体を含有する医薬組成物 | |
| TW202409010A (zh) | 人類呼吸道融合病毒及人類間質肺炎病毒之抑制劑 | |
| JP2019189573A (ja) | 縮合複素環および縮合炭素環誘導体を含有する、疼痛の治療および/または予防用医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13848316 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2015516335 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 14434013 Country of ref document: US |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| REEP | Request for entry into the european phase |
Ref document number: 2013848316 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2013848316 Country of ref document: EP |